Introduction {#s1}
============

Transcriptional gene activation and repression are essential for cell commitment, differentiation and homeostasis in metazoans. The dynamics of inducible gene expression have been characterised in exquisite detail ([@bib1]; [@bib12]; [@bib27]; [@bib63]; [@bib64]; [@bib29]; [@bib53]; [@bib57]). Compared to gene activation, the mechanisms that underpin gene repression have received less attention ([@bib4]; [@bib12]; [@bib21]; [@bib23]; [@bib26]; [@bib59]; [@bib62]). Understanding transcriptional repression is important because defects in gene silencing result in developmental abnormalities and disease ([@bib16]; [@bib66]). The nucleosome remodeling and deacetylase (NuRD) corepressor complex is critical for developmental gene regulation ([@bib13]; [@bib39]; [@bib54]; [@bib68]). NuRD malfunction leads to birth defects ([@bib20]) and underlies disease states ranging from autism spectrum disorders ([@bib68]; [@bib69]) to cancer ([@bib39]). NuRD is unique among corepressors in that it brings together histone deacetylation and ATP-dependent chromatin remodeling activities in the same complex, and therefore may have the necessary enzymatic attributes to convert active promoters into densely packed, hypoacetylated chromatin refractory to the transcriptional machinery. It has been argued that understanding the kinetics of changes in nucleosome positioning and modifications that accompany transcriptional repression is important to link the biochemical properties of NuRD with our understanding of chromatin-based gene regulation ([@bib16]). Meeting this challenge is difficult in experimental systems where the kinetics are slow ([@bib13]), or gene silencing is asynchronous ([@bib54]).

To investigate the sequence and causality of transcriptional repression mechanisms we focus on target genes of the NuRD-interacting transcriptional regulator Ikaros in B cell progenitors ([@bib22]). Ikaros is essential for B cell development ([@bib30]; [@bib33]; [@bib56]) and frequently mutated in B cell malignancies ([@bib46], [@bib47]). *Myc* and the prototypic pre-B cell gene *Igll1* are direct Ikaros target genes ([@bib22]; [@bib42]; [@bib60]). *Igll1* encodes an essential component of the pre-B cell receptor (pre-BCR), which initially drives pre-B cell proliferation ([@bib45]), but subsequently triggers the expression of the Ikaros paralog Aiolos ([@bib60]). Together, Ikaros and Aiolos orchestrate the silencing of *Igll1*, the termination of pre-BCR expression, cell cycle exit, and differentiation of pre-B cells ([@bib55]; [@bib60]). *Igll1* therefore is part of a regulatory circuit that controls the transition from self-renewal to differentiation of B cell progenitors. *Myc* is highly expressed in proliferating B cell progenitors and can interfere with B cell progenitor differentiation by overriding cell cycle exit ([@bib42]).

The interaction of Ikaros with the CHD4/Mi-2beta chromatin remodeling subunit of the NuRD co-repressor complex ([@bib36]) is direct ([@bib58]) and evolutionarily conserved ([@bib35]). Although histone deacetylation has been linked to Ikaros-mediated repression ([@bib38]), the mechanisms of Ikaros-mediated gene regulation remain incompletely understood. At the *Igll1* promoter the transcriptional activator EBF1 and Ikaros are thought to compete with each other for binding to a composite Ikaros/EBF1 site ([@bib55]; [@bib60]). Overlap between binding sites for Ikaros and transcriptional activators is also found the Ikaros target gene *Dntt* ([@bib19]; [@bib28]; [@bib62]), and the Ikaros-related Hunchback protein competes for DNA binding with transcriptional activators at Hox genes in *Drosophila* ([@bib40]). The concept of Ikaros-activator competition is supported by in vitro gel mobility shift experiments ([@bib60]; [@bib62]), but it remains unclear how such competition may play out in living cells.

Ikaros binds sequence motifs of gamma satellites, the core repeat unit of mouse pericentromeric heterochromatin ([@bib7], [@bib6]; [@bib11]; [@bib28]; [@bib37]). Silent genes are often positioned within transcriptionally repressive compartments of the nucleus ([@bib2]), including pericentromeric heterochromatin ([@bib7], [@bib6]), and the repositioning of *Rag* and *Dntt* loci accompanies stable, but not transient gene silencing ([@bib7]; [@bib59]). These data suggested the attractive model that Ikaros may position silent genes close to pericentromeric heterochromatin ([@bib7]; [@bib11]). Surprisingly, however, a direct role for Ikaros or NuRD in the repositioning of target genes has not been demonstrated ([@bib22]; [@bib60]).

To study transcriptional repression at high temporal resolution we utilize the regulated translocation of Ikaros from the cytoplasm to the nucleus ([@bib22]). Nuclear translocation results in immediate binding to target gene promoters, providing a clear path to target gene regulation. Using this approach we demonstrate that transcriptional repression is surprisingly rapid: promoters are depleted of RNAP2 and invaded by nucleosomes within minutes. Mechanistically, RNAP2 eviction is controlled by chromatin accessibility, not *vice versa*. Kinetic analysis reveals an unexpected temporal dissociation between NuRD enzymatic activities: CHD4-dependent remodeling - but not HDAC activity - initiates repression by excluding transcriptional activators and RNAP2. However, stable silencing and pericentromeric repositioning of Ikaros target genes require both nucleosome remodeling and HDAC activity. Hence, our high resolution view reveals that transcriptional repression involves complex and interdependent mechanisms, and that the enzymatic activities of CHD4 and HDACs are selectively required at different times and for discrete aspects of gene silencing.

Results {#s2}
=======

In vivo dynamics of Ikaros and EBF1 binding at the Ikaros target gene promoter *Igll1* {#s2-1}
--------------------------------------------------------------------------------------

Ikaros-ERt2 fusion proteins are retained in the cytoplasm of pre-B cells ([@bib22]) until their release by the ERt2 ligand 4-hydroxytamoxifen (4-OHT), which initiates the translocation of Ikaros-ERt2 within minutes ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Association with DAPI-dense pericentromeric gamma-satellite regions containing Ikaros binding sites ([@bib7], [@bib6]; [@bib28]) suggests that Ikaros binds DNA immediately after nuclear translocation. We exploited the temporal resolution afforded by inducible nuclear translocation to map the in vivo binding dynamics of Ikaros and EBF1 at the *Igll1* promoter, and to experimentally test whether Ikaros and EBF1 compete with each other ([@bib55]; [@bib60]).10.7554/eLife.22767.002Figure 1.Ikaros binding and EBF eviction have different kinetics.(**A**) Time course of nuclear translocation of HA-Ikaros-ERt2 induced by 4-OHT. The fraction of nuclear Ikaros-ERt2 was estimated by immunofluorescence staining for the HA tag (red) as \<5%, 20%, 50%, 80% and 95% at 0, 5, 15, 30 and 60 min after 4-OHT in 3 independent biological replicates. (**B**) ChIP-PCR time course of Ikaros and EBF1 binding at the *Igll1* promoter after 4-OHT. ChIP was done with antisera against the Ikaros C-terminus that detect Ikaros-ERt2 as well as pre-bound endogenous Ikaros. Log2 of mean ± SE, 3 independent biological replicates. Increased binding of Ikaros was significant by 5 min (p\<0.05, Students\' T test). Decreased binding of EBF1 was significant by 15 min. (**C**) The arrangement of binding sites for Ikaros (red) and EBF1 (green) at the *Igll1* promoter. (**D**) Two-state model with DNA binding sites occupied either by EBF1 or by Ikaros (EBF-DNA \<=\> Ikaros-DNA). Increase in Ikaros binding (red) comes at the expense of EBF binding (green). (**E**) Three-state model where a fraction of DNA binding sites is unbound at any moment in time (turquoise).**DOI:** [http://dx.doi.org/10.7554/eLife.22767.002](10.7554/eLife.22767.002)10.7554/eLife.22767.003Figure 1---source data 1.Numerical data used to generate [Figure 1B](#fig1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.003](10.7554/eLife.22767.003)10.7554/eLife.22767.004Figure 1---figure supplement 1.Nuclear translocation of Ikaros and 3- versus 4-state models of Ikaros-EBF competition.(**A**) Endogenous versus exogenous Ikaros abundance in the cytoplasm and the nucleus. Western blotting for exogenous Ikaros (anti-HA), total Ikaros (Ikaros C-terminal antibody), the cytoplasmic marker Tubulin and the nuclear marker histone H3 in whole cell lysate (W), cytoplasmic (C) and nuclear (N) fractions before and after 4-OHT addition. Mobility distinguishes endogenous Ikaros from the HA-Ikaros-ERt2 fusion protein. (**B**) Three-state model incorporating the gradual nature of the increase in nuclear Ikaros concentration predicts a steeper rise in Ikaros binding (red, arrows mark the increase in Ikaros binding during the first and second time period) until the available free DNA (turquoise) is depleted. The model also predicts little or no decrease in EBF1 binding (green) at equilibrium (arrowheads mark the impact of Ikaros translocation on EBF1 binding). (**C**) Introduction of an additional state where a fraction of transcription factor binding sites become inaccessible over time (blue, marked by a nucleosome in the cartoon model) capture key features of the Ikaros and EBF1 ChIP data in [Figure 1B](#fig1){ref-type="fig"}, namely diminishing increments in Ikaros binding (red, arrows mark the increase in Ikaros binding during the first and second time period) and a significant reduction in EBF1 binding at equilibrium (green, arrows mark the impact of Ikaros translocation on EBF1 binding).**DOI:** [http://dx.doi.org/10.7554/eLife.22767.004](10.7554/eLife.22767.004)

ChIP and quantitative PCR showed a steep rise in Ikaros binding to *Igll1* promoter within 5 min ([Figure 1B](#fig1){ref-type="fig"}). The *Igll1* promoter has two Ikaros sites, Ik1 at −83nt and Ik2 at −107nt from the *Igll1* TSS. An EBF motif is embedded in the Ik1 site, and gel mobility shift experiments demonstrate mutually exclusive binding of EBF1 and Ikaros ([@bib60]). Despite the presence of two additional EBF1 motifs at −198 and −228nt, the embedded EBF1 site is critical for *Igll1* promoter activity ([@bib48]) ([Figure 1C](#fig1){ref-type="fig"}). It was therefore surprising that the rise in Ikaros binding 5 min after 4-OHT was not accompanied by a corresponding fall in EBF1 binding ([Figure 1B](#fig1){ref-type="fig"}). Increased Ikaros binding without simultaneous eviction of EBF1 5 min after 4-OHT suggests that Ikaros does not directly displace EBF1.

We used kinetic modeling to explore the impact of increased nuclear Ikaros in the presence of a constant concentration of EBF1 and a constant number of *Igll1* promoter sites. In a 2-state model where DNA binding sites are either occupied by EBF1 or by Ikaros (EBF-DNA \<-\> Ikaros-DNA), any increase in Ikaros-DNA binding comes at the expense of EBF-DNA binding ([Figure 1D](#fig1){ref-type="fig"}). The observed temporal dissociation between Ikaros binding and EBF1 eviction by ChIP ([Figure 1B](#fig1){ref-type="fig"}) is inconsistent with direct competition between Ikaros (red) and EBF1 (green).

Interactions of transcription factors with target DNA are often transient, and not all target sites for DNA binding factors are occupied at any given time ([@bib18]; [@bib44]; [@bib51]; [@bib64]). We therefore considered a 3-state model ([Figure 1E](#fig1){ref-type="fig"}) where in addition to sites occupied by EBF1 or Ikaros a fraction of DNA binding sites is free at any given time (EBF-DNA, green \<-\> free DNA, turquoise \<-\> Ikaros-DNA, red). In this scenario, the initial increase in Ikaros binding does not displace EBF1 directly, but rather reduces the fraction of unbound sites. Eventually, the reduced availability of unbound sites impacts on EBF1 by reducing the chances of successful re-binding during dynamic cycles of unbinding and re-binding. Consistent with this prediction, EBF1 ChIP measured a gradual reduction in EBF1 binding between 15 and 60 min after 4-OHT ([Figure 1B](#fig1){ref-type="fig"}). This revised model explains how increased Ikaros occupancy of the *Igll1* promoter does not affect EBF1 binding immediately, but with a significant delay relative to the observed increase in Ikaros binding.

The abundance of nuclear Ikaros rises gradually over time ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), yet ChIP shows that Ikaros binding flattens out after 5 min and shows little or no further increase after 15 min, even though declining EBF1 binding should release potential binding sites ([Figure 1B](#fig1){ref-type="fig"}). While the models in [Figure 1C and D](#fig1){ref-type="fig"} assume a one-step increase in nuclear Ikaros, modeling an incremental rise in nuclear Ikaros predicted a more pronounced increase in Ikaros binding (red) with little or no decrease in EBF1 binding (green) at equilibrium ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). This does not reflect the experimental observations of a blunted rise in Ikaros binding and reduced EBF binding. The data were captured closely, however, when we allowed for the possibility that in response to the nuclear translocation of Ikaros the pool of DNA target sites available for binding decreases over time ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}, blue). We therefore investigated the impact of Ikaros on the chromatin state of target promoters.

Nuclear translocation of Ikaros evicts RNAP2 and positions nucleosomes that abrogate *Igll1* promoter accessibility {#s2-2}
-------------------------------------------------------------------------------------------------------------------

ChIP sequencing (ChIP-seq) showed that the nuclear translocation of Ikaros abolished RNAP2 binding to promoters and gene bodies of the target genes *Igll1* and *Vpreb1* ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) that are repressed by Ikaros ([@bib22]; [@bib60]). RNAP2 occupancy remained unchanged at the nearby *Top3b* promoter, which is not regulated by Ikaros ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).10.7554/eLife.22767.005Figure 2.Kinetics of Ikaros-mediated changes in RNAP2 occupancy, locus accessibility and transcription.(**A**) Ikaros triggers RNAP2 eviction and nucleosome recruitment at the *Igll1* promoter. RNAP2 ChIP-seq: pooled data from 4 independent biological replicates. MNase-seq: pooled data from 3 independent biological replicates. [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} shows the data for each individual replicate. (**B**) Kinetics of RNAP2 binding at *Igll1, Myc,* and *Zfp36* after 4-OHT by ChIP-PCR. Mean ± SE, n = 3. RNAP2 binding was significantly reduced at the *Igll1* promoter, gene body and TTS from 15 min and the *Myc* promoter from 30 min. (**C**) Kinetics of nucleosome occupancy at *Igll1, Myc,* and *Zfp36* after 4-OHT by MNase-PCR of 80--120 bp amplicons. 3 independent biological replicates. Nucleosome occupancy was significantly increased at the *Igll1* promoter and TSS from 5 min and the *Myc* promoter and TSS from 15 min. (**D**) Kinetics of primary *Igll1, Myc,* and *Zfp36* transcripts after 4-OHT by RT-PCR with primer pairs designed to span an intron-exon boundary (*Igll1* and *Myc*) or located within an intron (*Zfp36*). Mean ± SE, 4 independent biological replicates. Primary *Igll1* and *Myc* transcripts were significantly reduced from 15 and 5 min, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.005](10.7554/eLife.22767.005)10.7554/eLife.22767.006Figure 2---source data 1.Numerical data used to generate [Figure 2B,C and D](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.006](10.7554/eLife.22767.006)10.7554/eLife.22767.007Figure 2---figure supplement 1.Reproducibility of RNAP2 ChIP-seq and MNase-seq.The figure shows each individual replicate of the RNAP2 ChIP-seq and MNase-seq data summarised in [Figure 2A](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.007](10.7554/eLife.22767.007)10.7554/eLife.22767.008Figure 2---figure supplement 1---source data 1.Numerical data used to generate [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.008](10.7554/eLife.22767.008)

We mapped the nucleosome landscape before and after nuclear translocation of Ikaros using micrococcal nuclease digestion and sequencing (MNase-seq). Prior to nuclear translocation of Ikaros the *Igll1* promoter showed a nucleosome-free region that was occupied by RNAP2. Upon nuclear translocation of Ikaros this region became occluded by nucleosomes, and RNAP2 occupancy was reduced ([Figure 2A](#fig2){ref-type="fig"}, inset and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Reduced accessibility of the *Igll1* promoter is consistent with models where Ikaros and EBF1 compete for a decreasing number of accessible binding sites ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}).

Loss of RNAP2, reduced promoter accessibility, and transcriptional repression are early and near-simultaneous events {#s2-3}
--------------------------------------------------------------------------------------------------------------------

We next explored the dynamics of Ikaros-induced changes in RNAP2 occupancy, chromatin organisation and transcription at the Ikaros-repressed genes *Igll1* and *Myc*. ChIP-PCR demonstrated a rapid decrease in RNAP2 occupancy at the promoters, gene bodies and transcription termination sites (TTS) of Ikaros-repressed genes ([Figure 2B](#fig2){ref-type="fig"}). RNAP2 occupancy decreased at promoters, gene bodies, and the 3\' end of transcription units ([Figure 2B](#fig2){ref-type="fig"}), suggesting that Ikaros represses *Igll1* and *Myc* transcription by interfering with RNAP2 recruitment rather than elongation. Genome-wide, RNAP2 occupancy was significantly reduced at 372 downregulated genes 6 hr after Ikaros translocation ([Table 1](#tbl1){ref-type="table"}). The great majority of repressed genes with reduced RNAP2 occupancy showed a global reduction in RNAP2 binding to both the promoter and the gene body (324 of 372 or 87%). Only a small minority of repressed genes showed a block in RNAP2 elongation, as judged by preferential reduction of RNAP2 occupancy over the gene body (15 of 372 or 4% of genes with reduced RNAP2 occupancy). Hence, transcriptional repression of Ikaros target genes occurred by reduced RNAP2 recruitment, and a block in RNAP2 elongation was the exception.10.7554/eLife.22767.009Table 1.Ikaros represses transcription by interfering with RNAP2 recruitment rather than elongation. Analysis of differential gene expression (adj. p\<0.05) 360 min after 4-OHT-induced nuclear translocation of Ikaros in B3 cells, RNAP2 ChIP-seq, and the distribution of RNAP2 over the TSS and the gene body derived from RNAP2 ChIP-seq. RNAP2 occupancy was significantly decreased at only 40.3% (372 of 924) of genes downregulated at adj. p\<0.05 but increased to 62% when considering only genes downregulated with adj. p\<0.01 and a minimal log2 fold-change of 2. This suggests that the failure to detect decreased RNAP2 occupancy at the majority of downregulated genes may be due to the limited sensitivity of RNAP2 ChIP-seq compared to RNA-seq.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.009](10.7554/eLife.22767.009)10.7554/eLife.22767.010Table 1---source data 1.Numerical data used to generate [Table 1](#tbl1){ref-type="table"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.010](10.7554/eLife.22767.010)Gene expressionRNAP2 occupancy by ChIPGlobalTSS\~gene bodyTSS\>gene bodyTSS\<gene bodyUnchanged: 8799Unchanged: 812580194957Reduced: 4053781116Increased: 269256103Downregulated by Ikaros: 924Unchanged: 5495201217Reduced: 3723241533Increased: 3300Upregulated\
by Ikaros: 855Unchanged: 634615154Reduced: 6600Increased: 215200132

We assessed nucleosome occupancy of promoters and transcription start sites by PCR amplification of fragments protected from MNase digestion. Nucleosome occupancy increased with similar kinetics as RNAP2 eviction ([Figure 2C](#fig2){ref-type="fig"}).

We used quantitative RT-PCR with primers spanning intron-exon boundaries to quantify the abundance of unspliced (primary) transcripts, which are short-lived and serve as an indicator of transcriptional activity ([Figure 2D](#fig2){ref-type="fig"}). The abundance of *Igll1* and *Myc* primary transcripts was reduced within minutes of Ikaros translocation with similar kinetics as RNAP2 eviction and increased nucleosome occupancy ([Figure 2D](#fig2){ref-type="fig"}). These changes were selective for Ikaros-repressed genes, as illustrated by comparison with the Ikaros-induced gene *Zfp36* ([Figure 2C--D](#fig2){ref-type="fig"}).

RNAP2 is not required for maintaining chromatin accessibility at Ikaros target gene promoters {#s2-4}
---------------------------------------------------------------------------------------------

We next asked whether nucleosome invasion of Ikaros-repressed target promoters was secondary to reduced RNAP2 occupancy ([@bib25]) ([Figure 3A](#fig3){ref-type="fig"}, right). Triptolide triggers the global degradation of RNAP2 ([@bib43]; [@bib65]) and resulted in the near-complete loss of RNAP2 from whole cell lysates ([Figure 3A](#fig3){ref-type="fig"}, left) and from the *Igll1* and *Myc* promoters ([Figure 3B](#fig3){ref-type="fig"}, left; the inactive *Rex1* promoter is shown as a negative control). Loss of RNAP2 reduced promoter occupancy by the basal transcription factor TFIIB ([Figure 3B](#fig3){ref-type="fig"}, center) but, interestingly, the *Igll1* and *Myc* promoters remained sensitive to MNase in the absence of RNAP2 ([Figure 3B](#fig3){ref-type="fig"}, right). Hence, accessibility of Ikaros target gene promoters is not simply a consequence of RNAP2 occupancy.10.7554/eLife.22767.011Figure 3.RNAP2 is not required for chromatin accessibility of Ikaros target promoters.(**A**) Left: Western blotting for RNAP2 and TFIIB after 3 hr treatment with 1 uM triptolide (TPL). Tubulin is a loading control. 3 independent biological replicates. Right: Possible impact of RNAPII removal: promoters may remain nucleosome-free (top) or not (bottom). (**B**) RNAP2 ChIP-PCR, TFIIB ChIP-PCR and MNase-PCR at the indicated promoters following 4 hr of 1 μM triptolide or carrier (DMSO, grey). Mean ± SE, 3 independent biological replicates. Triptolide significantly reduced RNAP2 and TFIIB occupancy but did not significantly affect nucleosome occupancy at the *Igll1* and *Myc* promoters. (**C**) As (B) with 4-OHT present during the last hour. Mean ± SE, 3 independent biological replicates. Triptolide did not significantly affect the ability of Ikaros to increase nucleosome occupancy at the *Igll1* and *Myc* promoters.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.011](10.7554/eLife.22767.011)10.7554/eLife.22767.012Figure 3---source data 1.Numerical data used to generate [Figure 3B and C](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.012](10.7554/eLife.22767.012)10.7554/eLife.22767.013Figure 3---figure supplement 1.Nuclear translocation of Ikaros by proteolytic cleavage of Ikaros fusion proteins.(**A**) Schematic representation of Ikaros translocation induced by the proteolytic cleavage of Ikaros-TEV-ERt2 by Tobacco Etch Virus (TEV) protease. Ikaros-TEV-ERt2 fusion proteins are retained in the cytompasm until cleavage. The separate N- and C-termini of TEV protease are fused to FKBP and FRB, respectively. TEV activity is restored by the addition of rapamycin (R) ([@bib67]). Cleavage separates Ikaros from ERt2. The efficiency of inducible cleavage after rapamycin (2 hr, 25 nM) is monitored by western blotting using Ikaros antibodies (right). Actin was used as loading control. Representative of 3 independent biological replicates. (**B**) MNase digestion followed by PCR was used to determine changes in the accessibility of the *Igll1* and *Myc* promoters after triptolide-induced removal of RNAP2. The experiment complements the data shown in [Figure 3B and C](#fig3){ref-type="fig"}, but Split-TEV was used instead of 4-OHT-induced nuclear translocation of Ikaros. Split-TEV was activated by the addition of rapamycin at 25 nM for 2 hr. Mean ± SE, 3 independent biological replicates. Ikaros induction and tripolide-mediated RNAP2 depletion may synergise in increasing the nucleosome occupancy of the *Igll1* promoter.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.013](10.7554/eLife.22767.013)10.7554/eLife.22767.014Figure 3---figure supplement 1---source data 1.Numerical data used to generate [Figure 3---figure supplement 1A,B,C and D](#fig3s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.014](10.7554/eLife.22767.014)

We next compared the impact of Ikaros on target gene promoters in control and RNAP2-depleted cells. Nuclear translocation of Ikaros-ERt2 efficiently reduced the accessibility of the *Igll1* and *Myc* promoters even after RNAP2 depletion ([Figure 3C](#fig3){ref-type="fig"}).

To address the formal possibility that the ERt2 component of the Ikaros-ERt2 fusion protein contributed to the Ikaros-induced reduction in promoter accessibility we used a complementary approach where the nuclear translocation of Ikaros is triggered by the inducible cleavage of Ikaros-TEV-ERt2 fusion proteins ([@bib67]) ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). This confirmed that nuclear translocation of Ikaros in the absence of ERt2 was able to regulate promoter accessibility ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}).

The demonstration that the *Igll1* and *Myc* promoter regions remain accessible in the absence of RNAP2 mechanistically separates RNAP2 occupancy from promoter accessibility. We therefore focused on the question whether Ikaros controls promoter accessibility through active chromatin remodelling.

Ikaros controls promoter accessibility through the NuRD-associated chromatin remodeller Mi-2β/CHD4 {#s2-5}
--------------------------------------------------------------------------------------------------

We used RNA interference to deplete the NuRD-associated ATPase subunit Mi-2β/CHD4 encoded by *Chd4* ([Figure 4A](#fig4){ref-type="fig"}). CHD4 depletion substantially reduced the impact of Ikaros on the accessibility of the *Igll1* and *Myc* promoters ([Figure 4B](#fig4){ref-type="fig"}), indicating a key role for CHD4 in mediating Ikaros-induced nucleosome remodeling at the *Igll1* and *Myc* promoters. Ikaros-induced RNAP2 eviction and transcriptional repression were significantly delayed by *Chd4*-RNAi ([Figure 4C](#fig4){ref-type="fig"}), consistent with a role for CHD4-dependent chromatin remodeling in the silencing of Ikaros target genes.10.7554/eLife.22767.015Figure 4.Ikaros controls promoter accessibility through NuRD-associated chromatin remodeling.(**A**) Left: CHD4 expression in control and *Chd4* shRNA cells by western blotting. Tubulin is a loading control. One of 5 independent biological replicates. Right: Experimental outline. (**B**) MNase-PCR at the *Igll1* and *Myc* promoters in control (black) or *Chd4* shRNA cells (red) at the indicated times after 4-OHT. Mean ± SE, 3 independent biological replicates. *Chd4* shRNA significantly reduced the Ikaros-induced increase in nucleosome occupancy at 15, 30 and 120 min at the *Igll1* promoter and at 30 and 120 min at the *Myc* promoter. (**C**) RNAP2 ChIP-PCR (top) and MNase-PCR (bottom) at the *Igll1* and *Myc* promoters after 4-OHT in control (black) or Chd4 shRNA cells (red). Mean ± SE, 3 independent biological replicates. RNAP2 binding was significantly reduced in control cells but not in *Chd4* shRNA-treated cells from 5 to 120 min after 4-OHT at the *Igll1* and the *Myc* promoter. Primary transcripts were significantly reduced in control but not in *Chd4* shRNA-treated cells at 15 and 30 min for *Igll1* and at 30 and 120 min for *Myc*. (**D**) ChIP-PCR for CHD4 (black), MBD3 (grey) and BRG1 (orange) at the *Igll1* promoters at the indicated times after 4-OHT. Mean ± SE, 5 independent biological replicates for CHD4 and BRG1, 3 independent biological replicates for MBD3. CHD4 and MBD3 binding at the *Igll1* promoter were significantly increased from 5 to 60 min. BRG1 binding was significantly decreased from 30 to 120 min.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.015](10.7554/eLife.22767.015)10.7554/eLife.22767.016Figure 4---source data 1.Numerical data used to generate [Figure 4B,C and D](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.016](10.7554/eLife.22767.016)

We next assessed the impact of Ikaros on the association of NuRD components with the *Igll1* promoter. ChIP-PCR showed a rapid increase in the binding of the NuRD subunits CHD4 and MBD3 ([Figure 4D](#fig4){ref-type="fig"}). The onset CHD4 and MBD3 recruitment mirrored increased Ikaros binding after 4-OHT ([Figure 1B](#fig1){ref-type="fig"}). In contrast to Ikaros, increased binding of CHD4 and MBD3 was transient, returning close to their starting level by 6 hr ([Figure 4D](#fig4){ref-type="fig"}).

The SWI/SNF-associated chromatin remodeler BRG1 is antagonistic with Ikaros, and promotes the activity of Ikaros-repressed genes {#s2-6}
--------------------------------------------------------------------------------------------------------------------------------

CHD4 and the SWI-SNF-associated chromatin remodeler BRG1 can have antagonistic effects on transcriptional regulation ([@bib14]; [@bib24]; [@bib52]). To assess the relationship between Ikaros and BRG1 we compared genes regulated by Ikaros (See [Table 1---source data 1](#SD4-data){ref-type="supplementary-material"}) with genes regulated by BRG1 ([@bib3]). Genes activated by BRG1 were repressed by Ikaros (Odds ratio = 2.97, p=1.7×10^−30^) and vice versa (Odds ratio = 3.32, p=9.5×10^−31^). Conversely, Ikaros-repressed genes were depleted among BRG1-repressed genes (Odds ratio = 0.62) and vice versa (Odds ratio = 0.31; [Table 2](#tbl2){ref-type="table"}). This analysis indicates antagonistic regulation of target genes by Ikaros and BRG1.10.7554/eLife.22767.017Table 2.BRG1 promotes the expression of Ikaros-repressed genes. Shown is the overlap in differential gene expression (adj. p\<0.05) after 4-OHT-induced nuclear translocation of Ikaros in B3 cells and *Smarca4* deletion in B cell progenitors ([@bib3]).**DOI:** [http://dx.doi.org/10.7554/eLife.22767.017](10.7554/eLife.22767.017)\
Activated by BRG1Repressed by BRG1Downregulated by IkarosOdds ratio = 2.97\
p=1.7×10^−30^Odds ratio = 0.62\
p=0.99Upregulated\
by IkarosOdds ratio = 0.31\
p=1.00Odds ratio = 3.32\
p=9.5×10^−31^

NuRD recruitment and BRG1 eviction from Ikaros target gene promoters {#s2-7}
--------------------------------------------------------------------

At the peak of CHD4 and MBD3 binding, the *Igll1* promoter showed a marked decline in BRG1 binding ([Figure 4D](#fig4){ref-type="fig"}). BRG1 association with the *Igll1* promoter did not recover at later time points, when CHD4 and MBD3 binding returned to their starting levels ([Figure 4D](#fig4){ref-type="fig"}).

Histone deacetylase activity is dispensable for Ikaros-induced loss of RNAP2, reduced promoter accessibility and transcriptional repression {#s2-8}
-------------------------------------------------------------------------------------------------------------------------------------------

In addition to the chromatin remodeler CHD4, the NuRD complex contains the histone deacetylases HDAC1/2 ([@bib15]). Given the critical role for NuRD-associated chromatin remodeling activity in Ikaros-mediated gene silencing we asked whether HDAC activity was equally involved. Unexpectedly, broad inhibition of HDAC activity by trichostatin A (TSA) did not detectably interfere with Ikaros-induced loss of RNAP2, reduced promoter accessibility and early transcriptional repression of *Igll1* and *Myc* ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Application of the HDAC1/2 inhibitor MS-275 confirmed that Ikaros initiated the transcriptional downregulation of *Igll1* and *Myc* regardless of HDAC1/2 activity ([Figure 5B](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Similarly, HDAC inhibition did not interfere with the transcriptional downregulation of Ikaros target genes in primary pre-B cells ([Figure 5C](#fig5){ref-type="fig"}). To address the possibility that the ERt2 component of the Ikaros-ERt2 fusion protein might account for the apparent lack of HDAC activity in Ikaros-initiated gene silencing we performed experiments where the nuclear translocation of Ikaros was triggered by the inducible cleavage of Ikaros-TEV-ERt2 fusion proteins. TEV-induced nuclear translocation of Ikaros in the absence or ERt2 confirmed that HDAC activity was not required for the loss of accessibility ([Figure 5D](#fig5){ref-type="fig"}, left) or the transcriptional silencing of *Igll1* and *Myc* ([Figure 5D](#fig5){ref-type="fig"}, right).10.7554/eLife.22767.018Figure 5.Histone deacetylase activity is dispensable for initiating transcriptional repression.(**A**) MNase-PCR (left), RNAP2 ChIP-PCR (middle) and RT-PCR (right). Where indicated B3 cells were treated for 1 hr with 1 ng/ml TSA and/or 4-OHT. [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"} shows TSA effects on histone acetylation. Mean ± SE, 3 independent biological replicates. TSA did not significantly affect Ikaros-induced changes in nucleosome occupancy and RNAP2 binding to the *Igll1* and *Myc* promoter, or *Igll1* primary transcripts. (**B**) RT-PCR for primary *Igll1* and *Myc* transcripts in control or MS-275-treated cells (1 hr, 10 uM) before (grey) and 1 hr after 4-OHT (red). Mean ± SE, 3 independent biological replicates. [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"} shows effects of MS-275 on histone acetylation. MS-275 treatment weakly affected Ikaros-induced changes in *Igll1* primary transcripts and did not significantly affect Ikaros-induced changes in *Myc* primary transcripts. (**C**) RT-PCR for *Igll1*, *Myc* and the housekeeping gene *Ywhaz* in primary pre-B cells transduced with control (IRES-GFP) or Ikaros (Ikaros-IRES-GFP). Where indicated cells were treated with 1 ng/ml TSA. Mean ± SE, 3 independent biological replicates. [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"} shows TSA effects on histone acetylation. TSA did not significantly affect Ikaros-induced changes in *Igll1* and *Myc* primary transcripts. (**D**) MNase-PCR (left) and RT-PCR (right) at *Igll1* and *Myc* in control or TSA-treated cells (2 hr, 1 ng/ml) before (grey) and 2 hr after TEV cleavage-induced nuclear translocation of Ikaros (black). Mean ± SE, 3 independent biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.018](10.7554/eLife.22767.018)10.7554/eLife.22767.019Figure 5---source data 1.Numerical data used to generate [Figure 5A,B,C and D](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.019](10.7554/eLife.22767.019)10.7554/eLife.22767.020Figure 5---figure supplement 1.Changes in global and local histone acetylation in response to HDAC inhibitors and Ikaros.(**A**) The HDAC inhibitor TSA increases global (left) and local (right) acetylation of histones H3 and H4 at concentrations that do not interfere with the initiation of Ikaros-mediated gene silencing (1 ng/ml, see [Figure 5A](#fig5){ref-type="fig"}), 3 independent biological replicates. (**B**) The HDAC1/2-specific inhibitor MS-275 increases global (top) and local (bottom) acetylation of histones H3 and H4 at concentrations that do not interfere with the transcriptional downregulation of Ikaros target genes (see [Figure 5B](#fig5){ref-type="fig"}), 3 independent biological replicates. (**C**) ChIP-PCR was used to monitor Ikaros-induced changes in H3 and H4 acetylation. Mean ± SE, 3 independent biological replicates. (**D**) Prolonged treatment with 1 ng/ml of TSA over 24 hr increases global (left) and local (right) acetylation of histones H3 and H4 at *Igll1* and *Myc,* 3 independent biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.020](10.7554/eLife.22767.020)

These data demonstrate that - unexpectedly - HDAC activity is dispensable for Ikaros-induced repression. Consistent with this conclusion, ChIP experiments showed that although Ikaros reduced the acetylation of histone H3 and H4 at the target genes *Igll1* and *Myc*, the kinetics of histone deacetylation were markedly slower than those observed for reduced promoter accessibility, RNAP2 eviction, and the decline in primary transcripts ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). We saw no detectable increase in the trimethylation of H3K27 by PRC2 ([@bib50]) at the *Igll1* and *Myc* promoters 24 hr after nuclear translocation of Ikaros (Data not shown). Histone modifications are therefore not likely drivers for early events in Ikaros-mediated repression.

HDAC activity contributes to lasting repression and repositioning of Ikaros target genes to repressive nuclear compartments {#s2-9}
---------------------------------------------------------------------------------------------------------------------------

While the immediate transcriptional downregulation of Ikaros target genes was unaffected by HDAC inhibition ([Figure 5](#fig5){ref-type="fig"}), we found that Ikaros target gene transcription was not stably silenced 24 hr after Ikaros nuclear translocation in the presence of TSA ([Figure 6A](#fig6){ref-type="fig"}).10.7554/eLife.22767.021Figure 6.Histone deacetylation contributes to stable gene silencing.(**A**) RT-PCR showed that 1 ng/ml TSA for 24 hr significantly relieved Ikaros-induced reduced repression of *Igll* and *Myc* primary transcripts. Mean ± SE, 3 independent biological replicates. (**B**) MNase PCR showed that 1 ng/ml TSA for 24 hr did not significantly affect protection of 80--120 bp amplicons (short, left) but significantly reduced protection of 130--140 bp amplicons (long, right) at the *Igll1* promoter. Mean ± SE, 3 independent biological replicates. (**C**) ChIP-PCR to assess Ikaros-induced recruitment of histone H2B to the *Igll1* promoter between control cells and cells treated with 1 ng/ml TSA for 24 hr. Enrichment was normalised to total H3. Mean ± SE, 3 independent biological replicates. TSA significantly blunted the Ikaros-induced increase the H2B/H3 ratio at the *Igll1* promoter and TSS. (**D**) 3D DNA-FISH to monitor the position of *Igll1* alleles (green) relative to γ-satellite DNA (red, blue is DAPI). The percentage of *Igll1* alleles associated with γ-satellite DNA is shown as mean ± SE. Where indicated, cells were treated over night with TSA (1 ng/ml) and/or 4-OHT. At least 300 *Igll1* alleles were scored for each experimental condition across 3 independent biological replicates. The impact of TSA was statistically significant across replicates (p=9.54 × 10-18 GLM binomial logit).**DOI:** [http://dx.doi.org/10.7554/eLife.22767.021](10.7554/eLife.22767.021)10.7554/eLife.22767.022Figure 6---source data 1.Numerical data used to generate [Figure 6A,B,C and D](#fig6){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.022](10.7554/eLife.22767.022)

We examined the protection of nucleosome-associated DNA at the *Igll1* promoter and TSS using PCR amplicons of defined length ([Figure 6B](#fig6){ref-type="fig"}, top). TSA treatment for 24 hr did not affect Ikaros-induced nucleosome protection of short amplicons comprising 90--110 base pairs centred on peaks of MNase ([Figure 6B](#fig6){ref-type="fig"}, bottom left). In contrast, TSA reduced Ikaros-induced protection of longer amplicons of 130--140 bp, which represent the near complete length of 147 DNA base pairs associated with full nucleosomes ([Figure 6B](#fig6){ref-type="fig"}, bottom right). These data suggest that in the absence of HDAC activity, nucleosomes at the *Igll1* promoter and TSS may remain unstable ([@bib31]) or less evenly spaced. To address if this is due to missing H2A-H2B dimers we performed ChIP for histone H2B and H3. At the *Igll1* promoter and TSS, Ikaros triggered an increase in the occupancy not only of total histone H3, but also in the ratio of histone H2B over H3 ([Figure 6C](#fig6){ref-type="fig"}). Prolonged HDAC inhibition significantly blunted this increase in the H2B/H3 ratio ([Figure 6C](#fig6){ref-type="fig"}), indicating that HDAC activity facilitated the assembly of H2B-containing nucleosomes.

To test the role of Ikaros in the repositioning of target genes to the transcriptionally repressive environment of pericentromeric heterochromatin we carried out 3D DNA-FISH experiments. In the absence of 4-OHT, only a small minority (8%) of *Igll1* alleles (green) were associated with γ-satellite DNA (red), the repeat unit of mouse pericentromeric heterochromatin ([Figure 6D](#fig6){ref-type="fig"}). In contrast, most (78%) *Igll1* alleles were associated with γ-satellite DNA after 4-OHT ([Figure 6D](#fig6){ref-type="fig"}), indicating that increased nuclear Ikaros cells was sufficient for the repositioning of *Igll1* to pericentromeric heterochromatin. Ikaros-induced of *Igll1* repositioning was reduced to 55% of alleles by low doses (1 ng/ml) of TSA ([Figure 6D](#fig6){ref-type="fig"}). We note that under these conditions TSA effectively inhibited histone deacetylation ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) but did not globally disrupt nuclear organisation, since centromeric heterochromatin retained its compacted state and association with the nuclear periphery ([Figure 6D](#fig6){ref-type="fig"}).

Taken together, incomplete transcriptional silencing of *Igll1*, partial MNase protection of *Igll1* promoter DNA and incomplete repositioning of *Igll1* alleles to pericentromeric heterochromatin in the presence of HDAC inhibitors indicate that HDAC activity is required for full *Igll1* silencing, even though it is dispensable for the early events in transcriptional repression ([Figure 5](#fig5){ref-type="fig"}).

Interdependence of silencing mechanisms leveraged by Ikaros {#s2-10}
-----------------------------------------------------------

The experiments discussed above suggest that Ikaros may utilize silencing mechanisms not just sequentially, but also in a mutually interdependent fashion. We therefore asked whether CHD4-mediated chromatin remodeling contributes to the repositioning of *Igll1* loci. We found that the Ikaros-induced repositioning of *Igll1* alleles was severely impaired (from 78% to 13%) by knockdown of *Chd4* ([Figure 7A](#fig7){ref-type="fig"}). Pericentromeric repositioning of Ikaros target loci therefore requires NuRD-associated chromatin remodeling as well as HDAC activity.10.7554/eLife.22767.023Figure 7.Interdependence of silencing mechanisms leveraged by Ikaros.(**A**) 3D DNA-FISH to monitor the position of *Igll1* alleles (green) relative to γ-satellite DNA (red, blue is DAPI). The percentage of *Igll1* alleles associated with γ-satellite DNA is shown as mean ± SE. Where indicated, control or sh*Chd4* cells were treated over night with 4-OHT. At least 300 *Igll1* alleles were scored for each experimental condition across 3 independent biological replicates. The impact of *Chd4* knockdown was statistically significant across replicates (p=5.54×10-38 GLM binomial logit). (**B**) ChIP kinetics of Ikaros and EBF binding to the *Igll1* promoter in control (left) and sh*Chd4* cells (right). Increased binding of Ikaros to the *Igll1* promoter was significant for both control and sh*Chd4* cells, decreased binding of EBF1 was significant in control, but not in sh*Chd4* cells. Mean ± SE, 3 independent biological replicates. Ikaros and EBF1 binding at 15, 30 and 120 min were significantly higher in sh*Chd4* than control cells. (**C**) MNase-seq data from 3 independent biological replicates were integrated with Ikaros ChIP-seq data to show nucleosome occupancy at Ikaros binding peaks before and 6 hr after nuclear translocation of Ikaros. (**D**) Dynamics of Ikaros binding, RNAP2 eviction, loss of primary transcripts, nucleosome invasion, and histone deacetylation.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.023](10.7554/eLife.22767.023)10.7554/eLife.22767.024Figure 7---source data 1.Numerical data used to generate [Figure 7A and B](#fig7){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.024](10.7554/eLife.22767.024)

To explore the relationship between silencing mechanisms further, we revisited the models for competition between Ikaros and EBF1 for binding to the *Igll1* promoter ([Figure 1C,D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). We compared the kinetics of Ikaros and EBF1 binding to *Igll1* in control cells ([Figure 7B](#fig7){ref-type="fig"} left) and in *Chd4*-depleted cells ([Figure 7B](#fig7){ref-type="fig"} right, sh*Chd4*). *Chd4*-depleted cells showed a steeper rise in Ikaros binding between 5 and 15 min than control cells. Strikingly, the decrease in EBF1 binding seen in control cells was significantly blunted in the absence of CHD4. In this regard, the binding kinetics of Ikaros and EBF1 in the absence of CHD4 resembled a 3-state model ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) where an incremental increase in nuclear Ikaros concentration triggers a steep rise in Ikaros binding during the second time interval and results in little or no eviction of EBF1. In control cells, the observed dynamics more closely resembled a 4-state model ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) where Ikaros and EBF1 compete for binding sites that remain accessible. Consistent with a scenario where Ikaros not only displaces EBF1, but ultimately limits its own binding, integration of MNase-seq with Ikaros ChIP-seq showed that nuclear translocation of Ikaros increases nucleosome occupancy at Ikaros ChIP-seq peaks genome-wide ([Figure 7C](#fig7){ref-type="fig"}).

Discussion {#s3}
==========

Here we take a high-resolution view at transcriptional repression based on the inducible nuclear translocation of Ikaros. Nuclear translocation of Ikaros results in immediate binding to target gene promoters, providing a clear path to target gene regulation. Kinetic ChIP shows half-maximal binding of Ikaros to the *Igll1* target gene promoter within 5 min ([Figure 7D](#fig7){ref-type="fig"}). Unexpectedly, increased Ikaros binding did not directly displace the transcriptional activator EBF1 from the *Igll1* promoter, ruling out simple 2-state models where activator and repressor directly compete with each other. Ikaros effected half-maximal removal of RNAP2, transcriptional silencing and promoter invasion by nucleosomes within 12 min of nuclear translocation ([Figure 7D](#fig7){ref-type="fig"}).

Ikaros recruited the NuRD-associated chromatin remodeller CHD4 to target promoters, and CHD4 was required for the invasion of the *Igll1* and *Myc* promoters by nucleosomes, the exclusion of RNAP2, and the eviction of EBF1. Nuclear translocation of Ikaros reduced the accessibility of Ikaros binding sites genome-wide. Ultimately, Ikaros-induced chromatin remodeling limited the binding of the repressor itself, as evidenced by increased Ikaros binding after knockdown of *Chd4*. The binding kinetics of Ikaros and EBF1 at the *Igll1* promoter are best explained if a fraction of binding sites become inaccessible as a result of Ikaros nuclear translocation. Mechanistically, Ikaros can reduce EBF1 binding to the *Igll1* promoter only in the presence of CHD4, and EBF1 is binding is sensitive to local chromatin structure ([@bib61]).

The synchronous nature of our system enabled the detection of a transient increase in the association of the NuRD components CHD4 and MBD3 to Ikaros target promoters. Despite genetic evidence that NuRD is required for the differentiation of mouse embryonic stem cells, increased NuRD recruitment was not seen during this less synchronous process ([@bib54]). Coincident with increased NuRD recruitment, the SWI/SNF-associated chromatin remodeler BRG1 was evicted from the *Igll1* promoter. Ikaros and BRG1 were broadly antagonistic in B cell progenitors, since BRG1 was required for the activity of many Ikaros-repressed genes. BRG1 did not return to the remodeled *Igll1* promoter even after the binding of CHD4 and MBD3 declined, which may in part explain why promoter accessibility was not re-instated, suggesting that Ikaros-mediated NuRD recruitment and eviction of BRG1 may cooperate in the repression of Ikaros target genes.

Interestingly, our high-resolution view of Ikaros-mediated gene silencing indicates a temporal dissociation of enzymatic activities associated with NuRD where histone deacetylation occurred after chromatin remodelling and transcriptional repression ([Figure 7D](#fig7){ref-type="fig"}). CHD4, but not HDAC activity was required for reduced promoter accessibility, the loss of RNAP2, and transcriptional repression. Although dispensable for the initiation of transcriptional repression, HDAC activity did facilitate stable transcriptional silencing, nucleosome occupancy of target promoters, and locus repositioning to pericentromeric heterochromatin.

The silencing mechanisms delineated here are interdependent, as illustrated by the role of HDACs and the involvement of CHD4 in competition between Ikaros and EBF1 for access to the *Igll1* promoter, RNAP2 occupancy and locus repositioning to repressive nuclear environments, a hallmark of heritable gene silencing ([@bib7]; [@bib59]). Our data link locus repositioning to chromatin state by demonstrating that both histone deacetylation and CHD4-mediated chromatin remodeling contribute to efficient repositioning of the *Igll1* locus. Histone deacetylation and nucleosome positioning likely contribute to the compaction of the locus, facilitating \'like-with-like\' associations of chromatin states ([@bib34]).

Genes that are induced rapidly in response to TLR signaling in macrophages are often regulated at the level of transcriptional elongation ([@bib29]) and typically do not require ATP-dependent chromatin remodelling ([@bib53], [@bib52]). At the Ikaros target genes *Igll1* and *Myc* as well as genome-wide, RNAP2 recruitment, rather than RNAP2 elongation, was the primary mechanism by which Ikaros repressed RNAP2-dependent transcription. The role of RNAP2 was not to keep nucleosomes away from the *Igll1* and *Myc* promoters because experimental depletion of RNAP2 did not result in a loss of promoter accessibility. Experimental depletion of RNAP2 and the resulting loss of RNAP2-mediated transcription did not interfere with Ikaros-induced promoter remodelling. This is consistent with a direct role for Ikaros in target gene repression, and reminiscent of primary response gene induction in the absence of protein synthesis. With respect to the role of active chromatin remodeling, however, Ikaros-mediated repression was unlike the induction of primary response genes, and reminiscent of nuclear hormone receptor signaling where several enzymes cooperate to remodel chromatin within minutes of hormone addition ([@bib1]; [@bib27]; [@bib49]; [@bib63]).

The molecular determinants of whether IKAROS binding results in gene activation or repression remain to be explored. For genes that are repressed by Ikaros with fast kinetics, we favour a model where transcriptional repression by IKAROS involves active, CHD4-mediated chromatin remodeling of the *Igll1* and *Myc* target gene promoters. This restricts promoter access, excludes RNAP2 and the transcriptional activator EBF1, and ultimately limits binding of Ikaros itself. The emerging picture is that the rapid repression of developmentally regulated genes utilizes complex and interdependent mechanisms, and that complexity does not come at the expense of speed in transcriptional state transitions.

Materials and methods {#s4}
=====================

Cell culture {#s4-1}
------------

The B3 cell line was generated and characterised in our lab ([@bib6]). B3 and primary pre-B cells were maintained in Iscove\'s Modified Dulbecco\'s Medium (IMDM, Invitrogen), 10% FCS, penicillin and 100 μg/ml streptomycin) (GIBCO, Invitrogen). For primary pre-B cells, media were supplemented with β-mercaptoethanol, L-glutamine 100 U/ml, 5 ng/ml recombinant mouse IL-7 (R and D Systems) and ST-2 feeder cells. HA-Ikaros-ERt2-IRES-GFP or -Cherry in the MSCV retroviral vector was modified by insertion of a TEV protease recognition sequence to yield HA-Ikaros-TEV-ERt2-IRES-GFP or -Cherry and where indicated B3 cells were co-transfected with split-TEV constructs where the N- and C-termini of TEV protease were fused to FRB (FLAG-FRB-N_TEV- IRES-dsRED) and FKBP (FLAG-FKBP-C_TEV-IRES-CFP), respectively. Transduced cells were sorted by flow cytometry for homogeneous expression of constructs. MSCV HA-Ikaros-IRES-GFP and IRES-GFP control vectors, virus production and spin infection have been described.

Nuclear translocation of Ikaros-ERt2 was induced by Ikaros was induced by 0.5 µM 4-hydroxytamoxifen (4-OHT, Sigma-Aldrich) and TEV activity was induced by rapamycin (25 nM, Selleckchem). Nuclear translocation was monitored by anti-HA (Covance MMS-101R) immunofluorescence staining and confocal microscopy as described and images were processed using Leica and Image J software.

Where indicated, cells were treated with 1 μM triptolide (Sigma), 1 ng/ml trichostatin A (TSA, Sigma) or 10 μM MS-275 (Selleckchem).

shRNA for *Chd4* (5'-GACTACGACCTGTTCAAGCAG-3') and pQsupR control plasmid were used as advised by the manufacturer (Invitrogen) and media were supplemented with 20 μM pan caspase inhibitor (R and D Systems, FMK001).

Quantification of mRNA and protein expression {#s4-2}
---------------------------------------------

mRNA extraction, reverse transcription PCR and immunoblotting was as described. We used antibodies to histone H3 (Abcam AB1791), acetylated histone H3 (Abcam AB47915), acetylated histone H4 (Millipore 06--866), RNAPII (Santa Cruz sc-899), TFIIB (Santa Cruz sc-225), CHD4 (Abcam AB72418), and tubulin (Sigma T9026).

Chromatin accessibility by MNase and chromatin immunoprecipitation (ChIP) {#s4-3}
-------------------------------------------------------------------------

MNase digestion was done as described ([@bib8]; [@bib31]). Cells were cross-linked for 10 min at room temperature in 1% formaldehyde in 10% fixation buffer (0.5 mM EGTA pH 8.0, 100 mM NaCl, 1 mM EDTA, 50 mM HEPES pH 8.0, 10% formaldehyde). Fixation was stopped by glycine (140 mM). Cells were washed twice with cold PBS (4°C, 5 min, 900rcf) and resuspended in lysis buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP-40) supplemented with protease inhibitor cocktail (Roche), 0.15 mM spermine (Sigma), and 0.5 mM spermidine (Sigma) on ice for 20 min. Sample were washed and resuspended in MNase CaCl~2~+ buffer (10 mM Tris-HCl, pH 7.4, 15 mM NaCl, 60 mM KCl, 0.15 mM spermine, 0.5 mM spermidine) and digested with MNase (200 U/ml, Worthington) at in room temperature for 10 min. Digestion was stopped by 20 µl 100 mM EDTA, 10 mM EGTA per 2 × 10^6^ cells. As a control, an equal number of cells were treated in parallel without adding MNase. Samples were reverse crosslinked, DNA purified by phenol/chloroform and quantified (PicoGreen dsDNA quantitation kit, Life Technologies).

For MNase-qPCR, 2 ng DNA were used per qPCR reaction. Results were normalised to undigested controls and compared to the inactive *Rex1* or *αActin* promoter.

For MNase-seq, 50 ng DNA after MNase digestion (carrier ethanol treatment for 6 hr or 0.5 μM 4-OHT treatment for 6 hr) were used to prepare MNase-seq samples (Next Ultra, NEB) without size selection steps. Libraries from three biological replicates were sequenced (Illumina Hi-seq 2500, 50 bp paired end) to \~500--600 M reads per condition. Reads were aligned to mouse genome mm9 and reconstructed into complete fragments in silico. To calculate normalised coverage per base for MNase data, fragments with length between 110 bp and 170 bp were normalised to total reads outside of mm9 blacklisted regions.

Ikaros ChIP was as described using a C-terminal Ikaros antibody provided by Dr Stephen Smale that has been extensively characterised in ChIP-seq experiments ([@bib22]; [@bib3]). We used an EBF1 antibody (Santa Cruz sc-137065) previously characterised by ENCODE for EBF1 ChIP-seq. For RNAP2, chromatin remodeler and histone modification ChIP ([@bib5]) cells were fixed as described for MNase, lysed in 25 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.1% NP-40, pH 7.9 at 50 × 10^6^ cells/ml on ice for 15 min, centrifuged at 900 rcf for 10 min at 4°C, resuspended in 140 mM NaCl, 50 mM HEPES, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate, pH 7.9 and sonicated for 25 min at 4°C with 30 s on, and 30 s off (Bioruptor, Diagenode). Sonicated chromatin was recovered as supernatant after centrifugation at 25,000 rcf for 15 min at 4°C and incubated with antibodies to histone H3 (Abcam AB1791), acetylated histone H3 (Abcam AB47915), acetylated histone H4 (Millipore 06--866), RNAP2 (Santa Cruz sc-899), TFIIB (Santa Cruz sc-225), CHD4 (Abcam AB70469), MBD3 (Bethyl A302-528A) or Brg1 (Millipore, 07--478) on a rotating platform at 4°C overnight, washed sequentially in 140 mM NaCl, 50 mM HEPES, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate, pH 7.9 followed by 500 mM NaCl, 50 mM HEPES, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate, pH 7.9 followed by 250 mM LiCl, 50 mM HEPES, 1 mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate, pH 8.0 and finally 10 mM Tris-HCl, 1 mM EDTA, pH 7.5. Reverse crosslinked DNA was purified by phenol-chloroform extraction. For ChIP-seq, 10 ng ChIP and input DNA were used to prepare libraries (Next Ultra, NEB) with size selection for fragments between 100 and 300 bp. After 50 bp single-end sequencing (Hi-seq 2500, Illumina, \~155 M reads per condition), reads were aligned to mm9 using BWA version 0.7.5. SAM files were generated, aligned, sorted and indexed with samtools version 0.1.18. Duplicate reads were marked using Picard MarkDuplicates. The quality of the datasets and predicted fragment lengths were analysed using the ChIPQC Bioconductor package. Normalised BigWig files were generated using rtracklayer (version 1.3.2) with signal normalised to total mapped fragments per sample. ChIP-seq sample quality was assessed using ChIPQC (version 1.8.7) ([@bib9]). For the analysis of differential polymerase signal in genes and TSS regions, gene models for mm9 were retrieved from Ensembl Biomart. Total reads were counted within TSSs and gene bodies and analysis of differential binding performed using DEseq2 with efficiency and library complexity derived from ChIPQC supplied to the DEseq2 model as normalisation factors ([@bib41]). MNase signal over Ikaros ChIP-seq peaks ([@bib22]) was calculated using the Bioconductor soGGi package ([@bib17]) and differential MNase signal identified using the DChIPrep package ([@bib10]). Differential gene expression was based on a p-value of \<0.05 after Benjamini-Hochberg correction for multiple testing (adj. p\<0.05).

RT-PCR primers {#s4-4}
--------------

TargetForwardReverse*Igll1*GTGTCCACCACATACTTTCCCCACACTCATTCTAGCCTCTAGTCCGTG*Myc*TTCTCACCTGTGCCCTAACCGGTTTGCCTCTTCTCCACAG*Zfp36*GCTGGCTGGAAATGAGAGAGCCCCCTACCTCAACCTTAGC

MNase-PCR and ChIP-PCR primers {#s4-5}
------------------------------

TargetForwardReverse*Igll1* Prom. shortCTGTGAGTGAAAACAGTTAGGCTTGCACCAGCAGGCACACCCCAGTG*Igll1* Prom. longCAAACCCCAGGCTGTCTCTAGGCAGCTGTGAGTGAAAACA*Igll1* TSS shortGGTGGAAACTAGAGACAGCCTGGCGGCAAAAGGATTGTTCCTCC*Igll1* TSS longTGGCCAAAAGCTATTCCAGTGGGTAGTCCCTTTGGGAGAG*Igll1* +200 ntTGCTGTTGGGTCTAGTGGATGGGCCTGTTGCTTCCCACTGAAG*Igll1* +1.3 kbCAGCCAGTATCCCGACAAGTAGAATCTGCTGGGCCTGATA*Igll1* TTSACTGGGTTCCATGACTCCACTCACTGTCTTTCCTGTGCCTAA*Myc* Prom.CTCACTCAGCTCCCCTCCTCTCCCCTCCCTTCTTTTTCC*Myc* TSSAGGGATCCTGAGTCGCAGTCGCTCACTCCCTCTGTCTCT*Myc* +350 ntCCTAAGAAGGCAGCTCTGGAGCTGATGTTGGGTCAGTCG*Myc* +1 kbAACCAGAGGGAATCCTCACAGAACCGCTCAGATCACGACT*Myc* TTSGCCCAGTGAGGATATCTGGAACCGCAACATAGGATGGAGA*Zfp36* Prom.CATGCAAAATGTGCCTGAACCGCTACCATCACCTCCAGTT*Zfp36* TSSGAATGGCCTTGGTGAAGAGAGCCCCATAAAAGGAGAAAGC*Zfp36* +200 ntTACGCGAGTGACAGCAGTGTGCTGGCTGGAAATGAGAGAG*Zfp36* +0.6 kbCACTTCACGAGCTTGCCAGTAGTCAGGTTCTCCCTGGAGTT*Zfp36* TTSGGCTGGTAACGTCACTTCCTGGTGGGTAAACTGACCTCCA

To assess the impact of nuclear Ikaros on Ikaros-EBF1 competition, we implemented kinetic models of increasing complexity. First, we considered a 2-state model where DNAE and DNAI correspond to DNA bond by EBF1 and Ikaros with the binding rate constants are kE and kI ([Equation 1](#equ1){ref-type="disp-formula"}).$$\left\lbrack {DNA_{E}} \right\rbrack + Ikaros\ \rightleftharpoons\ \left\lbrack {DNA_{I}} \right\rbrack + EBF1$$

The corresponding rate equations are:$$\left\{ \begin{matrix}
\frac{d\left\lbrack {DNA_{E}} \right\rbrack}{dt} & {= - k_{I}\left\lbrack {Ikaros} \right\rbrack\left\lbrack {DNA_{E}} \right\rbrack + k_{E}\left\lbrack {EBF1} \right\rbrack\left\lbrack {DNA_{I}} \right\rbrack} \\
\frac{d\left\lbrack {DNA_{I}} \right\rbrack}{dt} & {= k_{I}\left\lbrack {Ikaros} \right\rbrack\left\lbrack {DNA_{E}} \right\rbrack - k_{E}\left\lbrack {EBF1} \right\rbrack\left\lbrack {DNA_{I}} \right\rbrack} \\
\end{matrix} \right.$$

To solve these rate equations by numerical integration we used KinTek Explorer (KinTek Corporation, Austin, TX; [@bib32]; [Figure 1D](#fig1){ref-type="fig"}). The 2-state model in [Equation 2](#equ2){ref-type="disp-formula"} cannot recapitulate the features observed in kinetic ChIP experiments ([Figure 1B](#fig1){ref-type="fig"}) using the estimated parametes Ikaros k~on~ 0.3 k~off~ 0.052; EBF1 k~on~ 0.036 k~off~ 0.033, or any other parameters tested. We therefore implemented a 3-state model that includes a population of free (unbound) DNA ([Equation 3](#equ3){ref-type="disp-formula"}).$$\left\lbrack {DNA_{E}} \right\rbrack\rightleftharpoons\left\lbrack {DNA} \right\rbrack\rightleftharpoons\left\lbrack {DNA_{I}} \right\rbrack$$

In this model, Ikaros and EBF1 can compete for the same binding site only if it is free. The EBF1 and Ikaros dissociation rate constants are k-E and k-I, respectively. The corresponding rate equations are in [Equation 4](#equ4){ref-type="disp-formula"}.$$\left\{ \begin{matrix}
{\frac{d\left\lbrack {DNA_{E}} \right\rbrack}{dt} = - k_{- E}\left\lbrack {DNA_{E}} \right\rbrack + k_{E}\left\lbrack {EBF1} \right\rbrack\left\lbrack {DNA} \right\rbrack} \\
{\frac{d\left\lbrack {DNA} \right\rbrack}{dt} = k_{- E}\left\lbrack {DNA_{E}} \right\rbrack + k_{- I}\left\lbrack {DNA_{I}} \right\rbrack - k_{E}\left\lbrack {EBF1} \right\rbrack\left\lbrack {DNA} \right\rbrack - k_{I}\left\lbrack {Ikaros} \right\rbrack\left\lbrack {DNA} \right\rbrack} \\
{\frac{d\left\lbrack {DNA_{I}} \right\rbrack}{dt} = k_{I}\left\lbrack {Ikaros} \right\rbrack\left\lbrack {DNA} \right\rbrack - k_{- I}\left\lbrack {DNA_{I}} \right\rbrack} \\
\end{matrix} \right.$$

Parameters were estimated as Ikaros k~on~ 0.3 k~off~ 0.052; EBF1 k~on~ 0.036 k~off~ 0.033, start conditions: I-DNA 0.1, E-DNA 0.1, free DNA 0.8, similar results were obtained with a range of parameters. The 3-state model recapitulates the primary features observed in the ChIP experiments ([Figure 1B,E](#fig1){ref-type="fig"}), but does not account for the gradual increase in nuclear Ikaros observed experimentally ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) or the possibility of binding site occupancy by nucleosomes (non-accessible DNA or DNAN). We introduced DNAN in a 4-state model ([Equation 5](#equ5){ref-type="disp-formula"}) where kN and k-N are the nucleosome binding and dissociation rate constants, respectively:$$\left\{ \begin{matrix}
{\frac{d\left\lbrack {DNA_{E}} \right\rbrack}{dt} = - k_{- E}\left\lbrack {DNA_{E}} \right\rbrack + k_{E}\left\lbrack {EBF1} \right\rbrack\left\lbrack {DNA} \right\rbrack} \\
{\frac{d\left\lbrack {DNA} \right\rbrack}{dt} = k_{- E}\left\lbrack {DNA_{E}} \right\rbrack + k_{- I}\left\lbrack {DNA_{I}} \right\rbrack + k_{- N}\left\lbrack {DNA_{N}} \right\rbrack} \\
{- k_{E}\left\lbrack {EBF1} \right\rbrack\left\lbrack {DNA} \right\rbrack - k_{I}\left\lbrack {Ikaros} \right\rbrack\left\lbrack {DNA} \right\rbrack - k_{N}\left\lbrack {Nucleosome} \right\rbrack\left\lbrack {DNA} \right\rbrack} \\
{\frac{d\left\lbrack {DNA_{I}} \right\rbrack}{dt} = k_{I}\left\lbrack {Ikaros} \right\rbrack\left\lbrack {DNA} \right\rbrack - k_{- I}\left\lbrack {DNA_{I}} \right\rbrack} \\
\end{matrix} \right.$$

We used the parameters Ikaros k~on~ 0.3 k~off~ 0.052; EBF1 k~on~ 0.036 k~off~ 0.033; nucleosome k~on~ 0.13 k~off~ 0.003, start conditions: I-DNA 0.1, E-DNA 0.1, free DNA 0.8, starting concentration of Ikaros: 0.1, Ikaros increment per time interval: 2.0 and obtained the kinetic curves shown in [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}. We experimentally tested the model predictions in kinetic ChIP experiments. Data from control cells ([Figure 7B](#fig7){ref-type="fig"}, left) correspond well to the 4-state model in [Equation 5](#equ5){ref-type="disp-formula"}, suggesting a role for nucleosomes in restricting binding of Ikaros and EBF1. Ikaros and EBF1 binding were increased in the absence of the nucleosome remodeler CHD4 ([Figure 7B](#fig7){ref-type="fig"}, right), in line with predictions by the 3-state model in [Equation 4](#equ4){ref-type="disp-formula"} without DNAN.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A high-resolution map of transcriptional repression\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom, David N Arnosti (Reviewer \#1), served as Guest Editor, and the evaluation has been overseen by Jessica Tyler as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Three reviewers have read your manuscript, and we agree that this work is potentially suitable for publication in *eLife*, after you have addressed points raised in the review process.

Essential revisions:

1\) Data reproducibility. A major point raised in the review process was whether the ChIP data shown represents biologically independent measurements or technical replicates from single preparations of chromatin. A number of experiments ([Figure 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}) show detailed measurements about protein occupancy or histone modification, but in some cases, the authors do not provide enough information about the data presented to allow the reader to judge if the changes measured are convincing demonstrations of biological processes. Specifically, for most of the ChIP measurements, the figure legend notes n=3; is that three measurements of single chromatin preparation, or three independent preparations, independently measured? Certain experiments (e.g. 4D) are described as \"independent experiments\", thus, the former cases may represent a single biological experiment (chromatin prep), with independent chromatin IP measurements. One line of evidence supporting this view is that individual figures have fairly tight error bars, yet vary quite a bit between experiments, e.g. RNAP drop in [Figure 3B,C](#fig3){ref-type="fig"} is 3-5 fold, while in [Figure 4C](#fig4){ref-type="fig"} the change is \~2 fold. The paper should clearly distinguish technical from biological replicates, and indicate if the results are supported by more than one experiment. Clearly, the strength of the conclusions is related to the reproducibility of the effects from separate observations.

2\) Relationship of findings to prior knowledge about Ikaros. A second point from the review was need to set the authors\' findings in a more general context, to show how information about HDAC, NuRD, and chromatin structure in regulation of Myc and Ipll1 supports or contradicts previous studies on Ikaros action. For instance, earlier work from Georgopoulos showed that on the CD4 intronic enhancer, Ikaros and NuRD appear to antagonize each other\'s activity, such that loss of CHD4 results in enhanced, not reduced Ikaros, activity. Similarly, previous studies have implicated basal factor pTefb-Ikaros interactions, as well as polycomb. Other studies have shown concomitant binding of Ikaros and Ebf1 at the Igll1 promoter in large pre-B cells where the gene is expressed, raising the question of whether Ikaros activates in this context. The paper would be much more valuable to the community if the authors integrate their findings better with previous work, and in the Discussion propose how similarities or differences are to be reconciled. As it stands, the main summary concluding the paper is rather superficial.

3\) Presentation and use of genome-wide data. The reviewers found that the integration of genome-wide information was potentially useful but incomplete; the quality of genome-wide information should be indicated with standard statistical measures (e.g. how much agreement is found among the triplicate MNase experiments? reproducibility of peaks etc.), even if the analysis of the entire dataset is being prepared in a separate study. MNase digestion patterns at two loci discussed, but overall significance is difficult to assess; is variation indicative of a change in nucleosome position, occupancy or other aspect of the individual experiments? It is not clear if the RNA pol II genome-wide study was similarly performed in triplicate. A related point to consideration of genome-wide data is related to point 2; it is reported that out of the 924 genes repressed upon increase in Ikaros expression, 372 show a reduction in RNAP2. How are the other 550 genes regulated? Are these not directly repressed by the Ikaros-NuRD complex? It would help this paper to provide enough information to understand [Table 1](#tbl1){ref-type="table"} and Supplementary Data [Table 1](#tbl1){ref-type="table"}, which enumerate and list genes affected by Ikaros. For instance, the two genes studied in detail here are direct targets of Ikaros, and show a loss of RNA Pol II. A large number, but not the majority of other repressed genes also show a loss of Pol II; which of these are expected to be direct targets? An additional point regarding the table is the lack of clarity of how genes are assigned to it -- is for example a log2 value of 0.05 even a significant change?

4\) Modeling. The reviewers had differing opinions about the modeling; some asked for further validation through additional measurements of actual nucleosome positioning and Ikaros occupancy at individual sites, while another view was that the models are useful enough to point toward future studies of mechanism. A justification of the application of the modeling would strengthen this aspect of the study. In addition, a clarification of the actual mechanism suggested is requested: Ikaros has been variously described as a recruiter of NuRD, or an antagonist, or binding in an overlapping manner at promoters but not enhancers. The kinetics of binding shown in 4D indicate that a model with simple, stable recruitment of NuRD by Ikaros is too simple. But it is not clear what mechanism the authors are proposing, based on their findings.

5\) Endogenous Ikaros vs. induced form. An increase in Ikaros nuclear localization is assumed from the immunofluorescence data but this is not a very quantitative method. A western blot analysis for Ikaros in the nuclear vs, cytoplasmic fractions at the different time points should be performed. The way the ChIP data is presented, it is not clear how much endogenous Ikaros is already present at the target promoters before the induction of the tamoxifen-regulated protein, and how this compares with the induced levels. Previous studies have already noted that Ikaros is present at these genes, so how much of the modifications are due to overexpression of the protein? Why would nucleosome changes results only from overexpression; is this a function of rapid interconversion between active and inactive states on the genes with only endogenous Ikaros? In addition, the paper is silent about the Ikaros-like Aiolos protein; is it present at these genes, and does it play a role in regulation under these conditions?

6\) MNase interpretation. The purported identification of \"fragile\" sites by MNase tests was not viewed as very strong, for a number of reasons. To identify such changes as an alternatively-bound form of the nucleosome, one would wish for a titration of MNase, not just a single digestion. In addition, it would be important to know if the change is due to a nucleosome shifting in position, rather than being weakly bound. Finally, the differential amplification in 6B with \"short\" and \"long\" amplicons may or may not be significant -- it is not clear if the n=3 is a technical replicate, in which case, the support is weak.

A number of technical points relating to reagents, methods, and data presentation should be addressed:

7\) The antibodies for Ikaros and EBF1 are not described; in the Materials and methods, a reference is made to Ferreiros-Vidal 2013, but EBF1 is not used there. What is the measure of specificity for these reagents? Is there other data to support the EBF1 binding shown here?

8\) In [Figure 1B](#fig1){ref-type="fig"}, \"enrichment\" is the measure of chromatin binding for Ikaros and EBF1. The Materials and methods don\'t describe how these calculations were performed. One way might be to measure the signal at some non-bound site, and divide the ChIP signal% input by this background control. If so, what is their defined background? What were the% input values for these promoters and other locations?

9\) For Pol II and TFIIB measurements, the manuscript shows directly the% input recovered from ChIP, which is a preferable approach for chromatin aficionados (their values \~1% are quite credible). The Y-axis is labeled \"enrichment\", however, which is confusing, because presumably the% input was not normalized to signal at another locus.

10\) In [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, part B, using the TEV-activated Ikaros system, depletion of Pol II does further affect MNase sensitivity, which is different from the system with 4-OHT induced Ikaros. The authors don\'t comment on this, though they previously make the point that Pol II eviction is not causing the changes in MNase sensitivity.

11\) [Figure 5](#fig5){ref-type="fig"}---figure supplement A: TSA treatment apparently induces a decrease in histone acetylation levels? Please comment.

12\) The differences for pericentric chromatin localization +/- TSA (6D) and loading of Ikaros with or without CHD4 (7B) may or may not be significant; it is not clear how reproducible these differences are in independent experiments. (See Point 1). In 6D, apparently two experiments were conducted; is this data from one?

13\) It is not clear why the KinTec modeling used the specific parameters indicated in Materials and methods. Have these been measured in a particular system?

14\) In subsection "Loss of RNAP2, reduced promoter accessibility, and transcriptional repression are early and near-simultaneous events" the authors state that they use primer pairs that span introns as a means to measure unspliced transcripts. They presumably mean primers that span individual exon/intron junctions? The primers used should be included in Materials and methods.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"A high-resolution map of transcriptional repression\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Jessica Tyler as Senior editor and a Reviewing editor.

The manuscript has been improved but there are four remaining issues that need to be addressed before acceptance, as outlined below:

In this revision of Liang et al., the authors have addressed the points raised in the first round of review. Regarding data reproducibility, the authors have indicated in figure legends which datasets are averages of multiple biological experiments, and which are representative. Additional experiments were performed for 3D FISH, and a [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} shows the reproducibility of ChIP and MNase experiments. Regarding previous observations about Ikaros action in different cell types and promoters, they clarify that their findings for c-myc and Igll1 promoters may represent just one side of this protein\'s regulatory activities, which includes activation at Zfp36.

The reviewers had asked for more specific analysis of genome-wide gene expression, since only a minority of genes showed the Pol II decrease found at the two promoters of interest. In the response to the reviewers, the authors reanalyze the data, and conclude that for a majority of promoters, it appears that Pol II decrease at the promoter is the trend, and that differences in sensitivity of measuring mRNA vs. Pol II occupancy may explain some of the discrepancy.

1\) In addition to having this information in the letter of response, the manuscript should indicate that they believe the majority of genes are showing reductions in Pol II, but that differential sensitivity may be an issue. Otherwise it seems the authors are content to ignore what might be a mechanism that impacts the majority of repressed genes.

The use and interpretation of the models were questioned; in response, the authors provide more information on modeling, and emphasize that their many biological measurements point away from the simple two-state model, where Ikaros directly dislodges EBF1. This conclusion seems to be strongly supported by the data. They emphasize the failure to find reasonable parameters for the simple model, rather than over-interpreting specific parameters for more complex models, which seems a reasonable conclusion.

The nature and quality of experiments from genome-wide experiments is better explained and illustrated by the additional supplemental figure noted above, by correlation analyses in the response letter, and data deposited in GEO.

In response to the question about how endogenous Ikaros figures into this system, the authors note that they find similar responses in CRISPR\'d cells lacking endogenous Ikaros, and show preliminary data in the letter. As asked, they also carry out a Western blot showing the levels of native and induced Ikaros over the time course, showing that the levels of the inducible form is approximately the same as that of the endogenous protein.

2\) The Western blot data should be included in the manuscript as part of, or attached to, [Figure 1](#fig1){ref-type="fig"}, where the system is introduced.

The interpretation of a \"fragile\" nucleosome state was questioned, based on the limited probing with one concentration of MNase. The authors carry out a titration, showing a similar trend, but also soften their conclusion, noting that it appears that it is either nucleosome depletion or movement that is affecting the repressed promoter.

A number of minor points were addressed including provenance of antibodies, figure labeling, and explanation in the figure legend that nascent RNA was measured with intron-exon boundary spanning primers.

3\) The text still refers to \"intron-spanning primers\" -- that needs to be fixed.

4\) Typo [Figure 7](#fig7){ref-type="fig"} Average nuceosome profile

10.7554/eLife.22767.036

Author response

Essential revisions:

1\) Data reproducibility. A major point raised in the review process was whether the ChIP data shown represents biologically independent measurements or technical replicates from single preparations of chromatin. A number of experiments ([Figure 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}) show detailed measurements about protein occupancy or histone modification, but in some cases, the authors do not provide enough information about the data presented to allow the reader to judge if the changes measured are convincing demonstrations of biological processes. Specifically, for most of the ChIP measurements, the figure legend notes n=3; is that three measurements of single chromatin preparation, or three independent preparations, independently measured? Certain experiments (e.g. 4D) are described as \"independent experiments\", thus, the former cases may represent a single biological experiment (chromatin prep), with independent chromatin IP measurements. One line of evidence supporting this view is that individual figures have fairly tight error bars, yet vary quite a bit between experiments, e.g. RNAP drop in [Figure 3B,C](#fig3){ref-type="fig"} is 3-5 fold, while in [Figure 4C](#fig4){ref-type="fig"} the change is \~2 fold. The paper should clearly distinguish technical from biological replicates, and indicate if the results are supported by more than one experiment. Clearly, the strength of the conclusions is related to the reproducibility of the effects from separate observations.

The number of experiments refers to independent biological replicates in all cases. Everything from cells/chemical treatment, chromatin/RNA isolation/digestion, ChIP/reverse transcription/PCR, library preparation and sequencing was done in the form of independent repeats on different days for the number of times indicated in the figure legends. We have added the term "independent biological replicates" to the revised figure legends to indicate this fact. The data are highly reproducible, as documented in the new [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} and the source data files supplied for each figure.

The difference between the drop in RNAP2 in [Figure 3B and C (3](#fig3){ref-type="fig"} to 5-fold) versus [Figure 4C](#fig4){ref-type="fig"} (\~2-fold) reflects the expression of IKAROS-IRES-GFP in 3B and C versus IKAROS-IRES-Cherry in [Figure 4A, B and C](#fig4){ref-type="fig"} where the cells were transduced with both inducible IKAROS and shRNA plasmids and expressed lower levels of IKAROS. Importantly, however, the responses obtained were consistent, as indicated by the SE from 3 independent biological replicates in [Figure 4A, B](#fig4){ref-type="fig"} and C.

2\) Relationship of findings to prior knowledge about Ikaros. A second point from the review was need to set the authors\' findings in a more general context, to show how information about HDAC, NuRD, and chromatin structure in regulation of Myc and Ipll1 supports or contradicts previous studies on Ikaros action. For instance, earlier work from Georgopoulos showed that on the CD4 intronic enhancer, Ikaros and NuRD appear to antagonize each other\'s activity, such that loss of CHD4 results in enhanced, not reduced Ikaros, activity. Similarly, previous studies have implicated basal factor pTefb-Ikaros interactions, as well as polycomb. Other studies have shown concomitant binding of Ikaros and Ebf1 at the Igll1 promoter in large pre-B cells where the gene is expressed, raising the question of whether Ikaros activates in this context. The paper would be much more valuable to the community if the authors integrate their findings better with previous work, and in the Discussion propose how similarities or differences are to be reconciled. As it stands, the main summary concluding the paper is rather superficial.

The paragraph above raises several important issues, and we have taken the liberty to structure it into 5 different points (i) to (v).

i\) The data reported in our manuscript do not in our view contradict previous reports, largely because no previous reports have examined the impact of IKAROS and NuRD on the time scale investigated here. However, it is worth noting that previous reports occasionally contradict each other. For example, there is marked disagreement between the Georgopoulos (Zhang et al. Nat Immunol. 2011, 13: 86-94) and Busslinger labs (Schwickert et al., 2014). We did not examine CHD4 positioning in Ikzf1-deficient cells, nor did we investigate the role of IKAROS, HDACs, or CHD4 at the proximal Cd4 enhancer (Williams et al., Immunity. 2004, 20: 719-33), which is active in T-cells but not in B-cells. Instead, we focus on Igll1 and Myc, which are repressed by IKAROS with fast kinetics, and by a mechanism that primarily depends on CHD4, and secondarily on HDAC activity. Importantly, not all IKAROS target genes are repressed by IKAROS. Our manuscript illustrates this by showing increasing chromatin accessibility, RNAP2 occupancy and transcriptional output for the IKAROS target gene Zfp36 in [Figure 2B, C](#fig2){ref-type="fig"}, and D). We have placed more emphasis on this in the revised manuscript by including the sentence "the molecular determinants of whether IKAROS binding results in gene activation or repression remain to be explored". We also point out that reduced RNAP2 occupancy, reduced accessibility and transcriptional repression "were selective for Ikaros-repressed genes, as illustrated by comparison with the Ikaros-induced gene Zfp36 ([Figure 2C-D](#fig2){ref-type="fig"})".

ii\) The link between IKAROS-mediated gene activation and P-TEFb (Bottardi et al., Nucleic Acids Res. 2011, 39: 3505--3519) is very interesting. We have not explored the biochemical interaction between IKAROS and P-TEVb directly. Among IKAROS-repressed genes, few are regulated at the level of RNAP2 elongation ([Table 1](#tbl1){ref-type="table"}). However, in line with your comment and with the findings of Bottardi et al., we saw a significant increase in RNAP2 occupancy at 215 genes that were upregulated by IKAROS ([Table 1](#tbl1){ref-type="table"}). Of these, 202 showed an increase of RNAP2 at both the TSS and the gene body, indicating that increased recruitment of RNAP2 to the TSS was accompanied by a corresponding increase in elongation events. Only 13 upregulated genes with increased RNAP2 binding showed an accumulation of RNAP2 at the TSS ([Table 1](#tbl1){ref-type="table"}). These data are consistent with a role for IKAROS in promoting transcriptional elongation at upregulated genes that show increased RNAP2 occupancy.

iii\) We have analysed the potential impact of the Polycomb repressive complex PRC2 (Oravecz et al., 2015) and found no increase in the PRC2-catalysed H3K27me3 mark at IKAROS-repressed genes within the 24 hour timeframe analysed in our study. This fact is indicated by the following sentence in our manuscript: "We saw no detectable increase in the trimethylation of H3K27 by PRC2 (Oravecz et al., 2015) at the Igll1 and Myc promoters 24h after nuclear translocation of Ikaros".

iv\) Our previous data provide support for the idea that both IKAROS and EBF1 bind the Igll1 promoter in large pre-B cells (Ferreiros-Vidal et al., 2013; Thompson et al., 2007). As pointed out by the referees, binding of Ikaros to the Igll1 promoter in large pre-B cells could potentially indicate a positive effect of IKAROS on Igll1 in large pre-B cells. To test this idea, we expressed a dominant negative form of Ikaros (IKAROS 159A). If IKAROS activates Igll1 in large pre-B cells, IKAROS 159A would be predicted to reduce Igll1 expression in large pre-B cells. Conversely, if IKAROS represses Igll1 in large pre-B cells, IKAROS 159A would be predicted to increase Igll1 expression. IKAROS 159A increased the expression of Igll1 (Thompson et al., 2007), demonstrating that Ikaros does not activate Igll1 in large pre-B cells.

v\) To address this point, we have changed our Results section to explicitly state that reduced RNAP2 occupancy, reduced accessibility and transcriptional repression "were selective for Ikaros-repressed genes, as illustrated by comparison with the Ikaros-induced gene Zfp36 ([Figure 2C-D](#fig2){ref-type="fig"})" and modified our discussion to a) acknowledge that "the molecular determinants of whether IKAROS binding results in gene activation or repression with fast or slow kinetics remain to be explored" and b) provide a more explicit account of our mechanistic interpretation of the data: "Mechanistically, Ikaros can reduce EBF1 binding to the Igll1 promoter only in the presence of CHD4, and EBF1 is binding is sensitive to local chromatin structure (Treiber et al., 2010)". "For genes that are expressed by Ikaros with fast kinetics, we favour a model where transcriptional repression by IKAROS involves active, CHD4- mediated chromatin remodeling of the Igll1 and Myc target gene promoters. This restricts promoter access, excludes RNAP2 and the transcriptional activator EBF1, and ultimately limits binding of Ikaros itself".

3\) Presentation and use of genome-wide data. The reviewers found that the integration of genome-wide information was potentially useful but incomplete; the quality of genome-wide information should be indicated with standard statistical measures (e.g. how much agreement is found among the triplicate MNase experiments? reproducibility of peaks etc.), even if the analysis of the entire dataset is being prepared in a separate study. MNase digestion patterns at two loci discussed, but overall significance is difficult to assess; is variation indicative of a change in nucleosome position, occupancy or other aspect of the individual experiments? It is not clear if the RNA pol II genome-wide study was similarly performed in triplicate. A related point to consideration of genome-wide data is related to point 2; it is reported that out of the 924 genes repressed upon increase in Ikaros expression, 372 show a reduction in RNAP2. How are the other 550 genes regulated? Are these not directly repressed by the Ikaros-NuRD complex? It would help this paper to provide enough information to understand [Table 1](#tbl1){ref-type="table"} and Supplementary Data [Table 1](#tbl1){ref-type="table"}, which enumerate and list genes affected by Ikaros. For instance, the two genes studied in detail here are direct targets of Ikaros, and show a loss of RNA Pol II. A large number, but not the majority of other repressed genes also show a loss of Pol II; which of these are expected to be direct targets? An additional point regarding the table is the lack of clarity of how genes are assigned to it -- is for example a log2 value of 0.05 even a significant change?

Author response [table 1](#tbl1){ref-type="table"} shows r2 correlation values between RNAP2 ChIP-seq replicates and experimental groups (4 independent biological replicates for control cells and 4 independent biological replicates for IKAROS-induced cells) as a standard statistical measure of reproducibility.

Genes\*TSS\*\*Gene bodies\*\*Mean of replicates0.9900.9650.977Mean of exp. groups0.9700.9140.931

Author response [table 1](#tbl1){ref-type="table"}. Reproducibility of RNAP2 ChIP-seq. Correlation values between RNAP2 ChIP- seq replicates and experimental groups, 4 independent biological replicates for control cells and 4 independent biological replicates for IKAROS-induced cells. \* Correlation values between RNAP2 ChIP-seq data for the 500 genes with the greatest total variation in RNAP2 ChIP-seq signal

across all samples, including replicates and experimental groups. \*\* Correlation values between RNAP2 ChIP-seq at all transcription start sites (TSS) and gene bodies that showed statistically significant differences in RNAP2 ChIP-seq signal between experimental groups.

[Author response image 1](#fig8){ref-type="fig"} shows correlation values between MNase-seq replicates and experimental groups (3 independent biological replicates for control cells and 3 independent biological replicates for IKAROS-induced cells) at the indicated loci (left) and a graphical representation of base-pair level correlations for MNase sensitivity at the Igll1 promoter.10.7554/eLife.22767.025Author response image 1.Reproducibility of MNase-seq.Correlation values between MNase-seq replicates and experimental groups at the indicated loci, 3 independent biological replicates for control cells and 3 independent biological replicates for IKAROS-induced cells (left). Base-pair level correlation for MNase sensitivity at the Igll1 promoter (right).**DOI:** [http://dx.doi.org/10.7554/eLife.22767.025](10.7554/eLife.22767.025)

We have added [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} to the revised manuscript to demonstrate the reproducibility of RNAP2 ChIP-seq and MNase-seq replicates.

Our study reports on 4 independent biological replicates of RNAP2 ChIP-seq data. We apologise for not making this clear in the original manuscript, and now indicate this clearly in the revised figure legends.

The focus of our analysis is on downregulated genes that show a significant reduction in RNAP2 binding, and the great majority of these show no evidence for increased RNAP2 pausing. The referees point out that of 924 genes downregulated at adj. p\<0.05, only 372 (40.3%) showed a significant reduction in RNAP2 ChIP-seq signal. For most of the remaining downregulated genes, the reduction in RNAP2 binding did not reach statistical significance. To test whether this is due to a difference in sensitivity between RNA-seq and RNAP2 ChIP-seq, we repeated our analysis considering only genes that were significantly downregulated and also showed a minimal log2 fold- change of 2. Of 174 genes that met these criteria, 95 showed a significant reduction in RNAP2 ChIP- seq signal (55%). The percentage of downregulated genes with significantly reduced RNAP2 ChIP- seq signal further increased to 62% when considering only genes downregulated with adj. p\<0.01. The finding that the majority of strongly downregulated genes had reduced RNAP2 ChIP-seq signals supports the idea that downregulated expression without reduced RNAP2 ChIP-seq signals is due at least in part to a difference in sensitivity between RNA-seq and RNAP2 ChIP-seq. Regardless of the criteria applied to define downregulated genes, reduced RNAP2 elongation remained an exception among IKAROS/NuRD-repressed genes: 4% (15/372) at adj. p\<0.05, 5.4% (5/93) at log2FC\>2 and p\<0.05, and 4.6% (4/87) at log2FC\>2 and p\<0.01.

Differential gene expression was defined by standard statistical criteria, namely a p-value of \<0.05 after Benjamini-Hochberg correction for multiple testing (adj. p\<0.05). We have added this information to the revised legend of [Table 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} and to the methods section.

4\) Modeling. The reviewers had differing opinions about the modeling; some asked for further validation through additional measurements of actual nucleosome positioning and Ikaros occupancy at individual sites, while another view was that the models are useful enough to point toward future studies of mechanism. A justification of the application of the modeling would strengthen this aspect of the study. In addition, a clarification of the actual mechanism suggested is requested: Ikaros has been variously described as a recruiter of NuRD, or an antagonist, or binding in an overlapping manner at promoters but not enhancers. The kinetics of binding shown in 4D indicate that a model with simple, stable recruitment of NuRD by Ikaros is too simple. But it is not clear what mechanism the authors are proposing, based on their findings.

The experimental finding that Ikaros binding increases prior to the displacement of EBF1 is based on 9 separate chromatin preparations and 9 separate ChIP experiments for each factor (3 shown in [Figure 1B](#fig1){ref-type="fig"}, [3](#fig3){ref-type="fig"} controls and 3 sh*Chd4* experiments shown in [Figure 7B](#fig7){ref-type="fig"}). In modeling these data, we cannot find parameters that would allow additional binding of Ikaros without simultaneous displacement of EBF1 in a 2-state model ([Figure 1D](#fig1){ref-type="fig"}). We are therefore confident that we can reject 2 state models.

Three-state models such as the one shown in [Figure 1E](#fig1){ref-type="fig"} can explain increased Ikaros binding prior to the displacement of EBF1. The parameters used are not critical, as long as the binding of Ikaros is as strong as or stronger than the binding of EBF1, which his seems reasonable given that Ikaros binds as an obligate dimer and a potential multimer.

The 3-state model in [Figure 1E](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} differ with respect to the increase in nuclear Ikaros. In [Figure 1E](#fig1){ref-type="fig"} Ikaros increases in a single step. In [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} Ikaros increases in several steps. This is based on immunofluorescence staining with antibodies to the Ikaros HA tag and semi-quantitative measurements of confocal images such as the ones shown in [Figure 1A](#fig1){ref-type="fig"}. The prediction that Ikaros binding should rise as a function of increasing nuclear concentration of Ikaros is robust to changes in parameters.

The 4-state model in [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"} assumes that nucleosome binding is more stable than TF binding. The prediction made by [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}/B is that loss of nucleosome remodeling will result to increased binding of Ikaros and reduced displacement of EBF1. To test this prediction, we performed ChIP experiments in control and sh*Chd4* cells. As shown in [Figure 7B](#fig7){ref-type="fig"}, Ikaros binding was increased, and the displacement of EBF1 was reduced after Chd4 knockdown. Hence, our conclusion that chromatin remodeling limits the binding of Ikaros and EBF1 is based on experimental data, and the models in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}/B illustrate how this finding might be explained.

We have added a new section that details the equations and parameters used for the modeling to the methods section of the revised manuscript. As requested, we have also added a paragraph summarising the mechanism we propose to explain our findings to the Discussion section of the revised manuscript: "we favour a model where transcriptional repression by IKAROS involves active, CHD4- mediated chromatin remodeling of the Igll1 and Myc target gene promoters. This restricts promoter access, excludes RNAP2 and the transcriptional activator EBF1, and ultimately limits binding of Ikaros itself".

5\) Endogenous Ikaros vs. induced form. An increase in Ikaros nuclear localization is assumed from the immunofluorescence data but this is not a very quantitative method. A western blot analysis for Ikaros in the nuclear vs, cytoplasmic fractions at the different time points should be performed. The way the ChIP data is presented, it is not clear how much endogenous Ikaros is already present at the target promoters before the induction of the tamoxifen-regulated protein, and how this compares with the induced levels. Previous studies have already noted that Ikaros is present at these genes, so how much of the modifications are due to overexpression of the protein? Why would nucleosome changes results only from overexpression; is this a function of rapid interconversion between active and inactive states on the genes with only endogenous Ikaros? In addition, the paper is silent about the Ikaros-like Aiolos protein; is it present at these genes, and does it play a role in regulation under these conditions?

As requested, [Author response image 2](#fig9){ref-type="fig"} shows endogenous versus exogenous Ikaros expression by western blotting for Ikaros in whole cell lysate, cytoplasmic and nuclear fractions before and after 4- OHT addition.10.7554/eLife.22767.026Author response image 2.Endogenous versus exogenous Ikaros expression.Western blotting for exogenous Ikaros (anti-HA), total Ikaros (Ikaros C-terminal antibody), the cytoplasmic marker Tubulin and the nuclear marker histone H3 in whole cell lysate (W), cytoplasmic (C) and nuclear (N) fractions before and after 4-OHT addition. Mobility distinguishes endogenous Ikaros from the HA-Ikaros-ERt2 fusion protein.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.026](10.7554/eLife.22767.026)

We have added the occupancy by endogenous Ikaros to the excel spread sheets listing the primary data for [Figures 1B](#fig1){ref-type="fig"} and [7B](#fig7){ref-type="fig"}. [Figure 7B](#fig7){ref-type="fig"} uses IKAROS_ERt2-IRES-Cherry, and 4-OHT increases Ikaros binding to Igll1 by 170% over endogenous Ikaros at 5 minutes and by 240% at 15 minutes. [Figure 1B](#fig1){ref-type="fig"} uses the more highly expressed IKAROS_ERt2-IRES-GFP, and 4-OHT increases Ikaros binding to Igll1 by 390% over endogenous Ikaros at 5 minutes and by 540% at 15 minutes. Both IKAROS-IRES-GFP and IKAROS-IRES-Cherry result in increased nucleosome occupancy, reduced RNAP2 occupancy and reduced transcriptional output, indicating that a moderate increase in Ikaros binding is sufficient to trigger the described responses.

Ikaros dosage in pre-B cells drives changes in gene expression that resemble the in vivo differentiation from large (Fr.C\') to small (Fr.D) pre-B cells (Ferreiros-Vidal et al., 2013). Ikaros is essential for the differentiation of large (Fr.C\') to small (Fr.D) pre-B cells (Heizmann et al., 2013; Joshi et al., 2014; Schwickert et al., 2014), and the majority of Ikaros target genes are already bound by Ikaros in large (Fr.C\') pre-B cells (Ferreiros-Vidal et al., 2013). The Ikaros family member Ikzf3 is upregulated between the large (Fr.C\') and small (Fr.D) pre-B cell stage (Thompson et al., 2007), and increased Ikaros/Aiolos expression drives increased binding to target gene promoters (Thompson et al., 2007; Ferreiros-Vidal et al., 2013). Hence, Ikaros dosage is critical for the impact of Ikaros on gene expression. Inducible translocation of Ikaros into the nucleus is intended to model the increase in the expression of Ikaros family proteins during the differentiation of large (Fr.C\') to small (Fr.D) pre- B cells. Accordingly, our system aims to moderately increase Nuclear Ikaros dosage, as illustrated by western blotting for Ikaros in whole cell lysate, nuclear and cytoplasmic fractions before and after 4- OHT addition ([Author response image 2](#fig9){ref-type="fig"}).

These data indicate that nuclear Ikaros dosage translates into the regulation of Ikaros target genes, including Igll1, Myc, and other genes where Ikaros binding is seen in large pre-B (Fr.C\') cells.

Nucleosome changes and repression of Igll1 and Myc result from an increase in the nuclear dosage and increased target gene binding of Ikaros and/or Aiolos. In B cell differentiation in vivo, both Igll1 and Myc are downregulated as Fr.C\' cells progress to Fr.D (www.immgen.org).

Both (highly expressed) IKAROS-IRES-GFP and (moderately expressed) IKAROS-IRES-Cherry result in increased nucleosome occupancy, reduced RNAP2 occupancy and reduced transcriptional output. This indicates that a moderate increase in Ikaros expression and binding is sufficient to trigger the described responses.

To explore the relationship between endogenous and exogenous Ikaros we repeated Ikaros induction experiment in B3 cells in which we targeted both endogenous Ikzf1 alleles by CRISPR/Cas9. In these cells, repression of Igll1 and Myc (and induction Zfp36) occurred after Ikaros-ERt2 induction with kinetics similar to those we found in B3 cells with intact endogenous Ikzf1 alleles ([Author response image 3](#fig10){ref-type="fig"}). These data indicate that Ikaros-mediated transcriptional repression can occur with fast kinetics in the absence of endogenous Ikaros.10.7554/eLife.22767.027Author response image 3.Transcriptional regulation by Ikaros-ERt2 in the absence of endogenous Ikaros.B3 cells with disrupted endogenous Ikzf1 alleles were transduced with Ikaors-ERt2. Primary transcripts for Igll1, Myc, and Zfp36 were measured at the indicated times after 4-OHT addition. Mean**DOI:** [http://dx.doi.org/10.7554/eLife.22767.027](10.7554/eLife.22767.027)

± SE of 3 independent biological replicates.

\</[Author response image 3](#fig10){ref-type="fig"} title/legend\>

BLNK-mediated upregulation of Ikzf3 results in the repression of Igll1 (Thompson et al., 2007), and Ikaros and Aiolos both repress Myc (Ma et al., 2010).

6\) MNase interpretation. The purported identification of \"fragile\" sites by MNase tests was not viewed as very strong, for a number of reasons. To identify such changes as an alternatively-bound form of the nucleosome, one would wish for a titration of MNase, not just a single digestion. In addition, it would be important to know if the change is due to a nucleosome shifting in position, rather than being weakly bound. Finally, the differential amplification in 6B with \"short\" and \"long\" amplicons may or may not be significant -- it is not clear if the n=3 is a technical replicate, in which case, the support is weak.

As discussed in section 1, our conclusions are based on independent biological replicates and the data are solid. MNase titration followed by quantitative PCR confirmed that TSA treatment reduced the protection of long amplicons at the Igll1 promoter 24h after Ikaros induction ([Author response image 4](#fig11){ref-type="fig"}). Nevertheless, without additional sequencing experiments we cannot be certain whether histone deacetylase inhibition reduces nucleosome stability or alters nucleosome positioning. We have therefore modified the narrative of our revised manuscript as follows: "These data suggest that in the absence of HDAC activity, nucleosomes at the Igll1 promoter and TSS may remain unstable (Henikoff et al., 2011) or less evenly spaced". What is clear, however, is that (i) Ikaros changes nucleosome occupancy of the Igll1 promoter and (ii) HDAC inhibition affects nucleosome occupancy of the Igll1 promoter after 24 hours.10.7554/eLife.22767.028Author response image 4.Titration experiments confirm the impact of HDAC inhibition on MNase protection of *Igll1* promoter chromatin.MNase titration followed by quantitative PCR showed that 1ng/ml TSA for 24 hours did not significantly affect protection of 80-120 bp amplicons (short, left) but significantly reduced protection of 130-140 bp amplicons (long, right) at the Igll1 promoter. Mean ± SE of 3 independent biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.028](10.7554/eLife.22767.028)

A number of technical points relating to reagents, methods, and data presentation should be addressed:

7\) The antibodies for Ikaros and EBF1 are not described; in the Materials and methods, a reference is made to Ferreiros-Vidal 2013, but EBF1 is not used there. What is the measure of specificity for these reagents? Is there other data to support the EBF1 binding shown here?

We apologise for these omissions and have added the following sentences to the methods section: "Ikaros ChIP was as described (Ferreiros-Vidal et al., 2013) using a C-terminal Ikaros antibody provided by Dr Stephen Smale that has been extensively characterised in ChIP-seq experiments (Ferreiros-Vidal et al., 2013; Bossen et al., 2015). We used an EBF1 antibody (Santa Cruz sc- 137065) previously characterised by ENCODE for EBF1 ChIP-seq". Additional support for the Ikaros and EBF1 binding shown here comes from Schwickert et al., 2014, for EBF1 (using a V5 epitope tag- specific reagent), Ferreiros-Vidal et al., 2013, for HA-Ikaros (using a HA epitope tag-specific reagent), Ferreiros-Vidal et al., 2013, for endogenous Ikaros (using the C-terminal Ikaros antibody employed in this study) and Bossen et al., 2015, for endogenous Ikaros (also using the C-terminal Ikaros antibody employed in this study) as summarised in [Author response image 5](#fig12){ref-type="fig"}.10.7554/eLife.22767.029Author response image 5.Additional support for Ikaros and EBF1 binding at the *Igll1* promoter in B cell progenitors.V5 epitope tag-specific EBF1 ChIP and input (top, Schwickert et al., 2014), ChIP for endogenous Ikaros using the C-terminal Ikaros antibody employed in this study (Bossen et al., 2015; Ferreiros-Vidal et al., 2013), HA-tagged Ikaros using a HA epitope tag-specific reagent (Ferreiros-Vidal et al., 2013) and input (Ferreiros-Vidal et al., 2013) show binding of EBF1 and Ikaros to the *Igll1* promoter.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.029](10.7554/eLife.22767.029)

8\) In [Figure 1B](#fig1){ref-type="fig"}, \"enrichment\" is the measure of chromatin binding for Ikaros and EBF1. The Materials and methods don\'t describe how these calculations were performed. One way might be to measure the signal at some non-bound site, and divide the ChIP signal% input by this background control. If so, what is their defined background? What were the% input values for these promoters and other locations?

[Figure 1B](#fig1){ref-type="fig"} and [7B](#fig7){ref-type="fig"} compare ChIP signals (% input) at each time point to ChIP signals (% input) before 4-OHT addition (0min). We measured ChIP signals at control loci as part of our quality control, but not for the purpose of normalisation. EBF1 and Ikaros ChIP signals for the pluripotency-related Rex1 locus are shown in [Author response image 6](#fig13){ref-type="fig"}.10.7554/eLife.22767.030Author response image 6.EBF1 and Ikaros ChIP at *Igll1* compared to the control locus *Rex1*.The data shown are for B cells transduced with Ikaros-IRES-Cherry and represent the mean ± SE of 3 independent biological replicates. The data have been added to the source data file for [Figure 7B](#fig7){ref-type="fig"} of the revised manuscript.**DOI:** [http://dx.doi.org/10.7554/eLife.22767.030](10.7554/eLife.22767.030)

\</[Author response image 6](#fig13){ref-type="fig"} title/legend\>

9\) For Pol II and TFIIB measurements, the manuscript shows directly the% input recovered from ChIP, which is a preferable approach for chromatin aficionados (their values \~1% are quite credible). The Y-axis is labeled \"enrichment\", however, which is confusing, because presumably the% input was not normalized to signal at another locus.

All ChIP-PCR data in our manuscript are% input or fold-changes thereof. "Enrichment" was added to the Y-axes simply to indicate that these are ChIP experiments, not to indicate normalisation to a reference locus. We have changed the relevant axes to "% input".

10\) In [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, part B, using the TEV-activated Ikaros system, depletion of Pol II does further affect MNase sensitivity, which is different from the system with 4-OHT induced Ikaros. The authors don\'t comment on this, though they previously make the point that Pol II eviction is not causing the changes in MNase sensitivity.

The main points of this experiment are to show (i) that Igll1 promoter accessibility is maintained in the absence of RNAP2 and (ii) Ikaros induction can still induce chromatin remodeling in triptolide-treated cells. [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, part B supports these conclusions. Thank you for pointing out that Ikaros induction via split TEV induction causes an even greater increase in nucleosome occupancy of the Igll1 promoter, suggesting synergy between Ikaros induction and RNAP2 depletion. We have added the following sentence to the legend of [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, part B: "Ikaros induction and tripolide- mediated RNAP2 depletion may synergise in increasing the nucleosome occupancy of the Igll1 promoter".

11\) [Figure 5](#fig5){ref-type="fig"}---figure supplemental Figure part A: TSA treatment apparently induces a decrease in histone acetylation levels? Please comment.

As the referees point out, TSA treatment can have moderate effects on local histone acetylation prior to Ikaros induction ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}), as well as local RNAP2 occupancy and primary transcript levels prior to Ikaros induction ([Figure 5A](#fig5){ref-type="fig"}). This is consistent with proposals that acetylation/deacetylation cycles may promote transcription (Wang et al., Cell 2009, 138: 1019-1031; Perissi et al., Nat Rev Genet 2010, 11: 109--123). Importantly, TSA increased global H3 and H4 acetylation ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}, left) and ChIP experiments in the same panel show that TSA prevents Ikaros-induced local deacetylation of H3 and H4 at the Igll1 and Myc promoters. In the cells used for these ChIP experiments, TSA did not interfere with the Ikaros-induced increase in nucleosome occupancy, reduction in RNAP2 occupancy, and transcriptional repression ([Figure 5A](#fig5){ref-type="fig"}), supporting our conclusion that HDAC activity is not required for the Ikaros-induced increase in nucleosome occupancy, reduction in RNAP2 occupancy, and transcriptional repression.

12\) The differences for pericentric chromatin localization +/- TSA (6D) and loading of Ikaros with or without CHD4 (7B) may or may not be significant; it is not clear how reproducible these differences are in independent experiments. (See Point 1). In 6D, apparently two experiments were conducted; is this data from one?

We have performed additional DNA-FISH experiments, and the revised [Figures 6D](#fig6){ref-type="fig"} and [7A](#fig7){ref-type="fig"} now show results for 3 independent biological replicates with mean and SE. A total of 1233 alleles were scored, 355 for control cells, 314 after Ikaros induction, 248 for Ikaros in the presence of TSA, and 316 for Ikaros in sh*Chd4* cells. The p-values as calculated based on replicates using GLM (binomial logit) were 9.54x10-18 for the effect of TSA and 5.54x10-38 for the effect of Chd4 knockdown, indicating that the effect of TSA and Chd4 knockdown on the positioning of Igll1 alleles were statistically significant. The figures, legends and source files of the revised manuscript have been updated accordingly.

13\) It is not clear why the KinTec modeling used the specific parameters indicated in Materials and methods. Have these been measured in a particular system?

As discussed in detail in section 4, the models were largely robust to parameter choices, and our choices were based on the greater stability of nucleosomes compared to transcription factors, and the knowledge that Ikaros binds as an obligate dimer/facultative multimer. The rate of nuclear Ikaros was estimated based on semi-quantitative confocal microscopy.

14\) In subsection "Loss of RNAP2, reduced promoter accessibility, and transcriptional repression are early and near-simultaneous events" the authors state that they use primer pairs that span introns as a means to measure unspliced transcripts. They presumably mean primers that span individual exon/intron junctions? The primers used should be included in Materials and methods.

Thank you for pointing out the inaccurate phrasing. The primer pairs used were "designed to span an intron-exon boundary". We have corrected this in the revised manuscript. Primer sequences are listed in the Methods section of the revised manuscript.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

The reviewers had asked for more specific analysis of genome-wide gene expression, since only a minority of genes showed the Pol II decrease found at the two promoters of interest. In the response to the reviewers, the authors reanalyze the data, and conclude that for a majority of promoters, it appears that Pol II decrease at the promoter is the trend, and that differences in sensitivity of measuring mRNA vs. Pol II occupancy may explain some of the discrepancy.

1\) In addition to having this information in the letter of response, the manuscript should indicate that they believe the majority of genes are showing reductions in Pol II, but that differential sensitivity may be an issue. Otherwise it seems the authors are content to ignore what might be a mechanism that impacts the majority of repressed genes.

We have changed the narrative to "Genome-wide, RNAP2 occupancy was significantly reduced at 372 downregulated genes 6 hours after Ikaros translocation ([Table 1](#tbl1){ref-type="table"})" and added to following information to the legend of [Table 1](#tbl1){ref-type="table"}: "RNAP2 occupancy was significantly decreased at only 40.3% (372 of 924) of genes downregulated at adj. p\<0.05 but increased to 62% when considering only genes downregulated with adj. p\<0.01 and a minimal log2 fold-change of 2. This suggests that the failure to detect decreased RNAP2 occupancy at the majority of downregulated genes may be due to the limited sensitivity of RNAP2 ChIP-seq compared to RNA-seq".

2\) The Western blot data should be included in the manuscript as part of, or attached to, [Figure 1](#fig1){ref-type="fig"}, where the system is introduced.

We have added a western analysis showing the levels of native and induced Ikaros over time to [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}. A description of the experiment has been added to the figure legend, and the figure is referred to in the main text where the system is introduced.

3\) The text still refers to \"intron-spanning primers\" -- that needs to be fixed.

We have fixed the offending sentence on p10 of the manuscript to read: "We used quantitative RT-PCR with primers spanning intron-exon boundaries to quantify the abundance of unspliced (primary) transcripts..."

4\) Typo [Figure 7](#fig7){ref-type="fig"} Average nuceosome profile

We have corrected the typo in [Figure 7](#fig7){ref-type="fig"} to "nucleosome profile"

[^1]: AstraZeneca, Cambridge Science Park, Cambridge, United Kingdom.
